Robert Martin
Real-world effectiveness of epretamab in relapsed or refractory large B-cell lymphoma: a multicenter dutch cohort
Christina Schulz
Single-cell profiling reveals leukemic stem cell persistence in acute myeloid leukemia (AML)
David Evans
Long-term outcomes of AL amyloidosis treated with autologous stem cell transplantation: a French registry study of 112 patients
María Ortiz
Efficacy and safety of exacatogene autotemcel in patients receiving CD19-directed CAR T-cell therapy: primary analysis of the phase 1 HORIZON-9 study
Jan Koch
Efficacy and safety of anicavocel in high-risk smoldering myeloma: primary analysis of the phase 1b/2 ECLIPSE-2 study
David Nelson
Long-term outcomes of patients with invasive fungal infections treated with antifungal prophylaxis: a multinational registry study of 1240 patients
Camilla Jørgensen
Efficacy and safety of corvalimab in children with high-risk B-cell ALL: primary analysis of the randomized phase 2 HELIOS-8 study
Iván Díaz
Anicavocel versus carfilzomib and dexamethasone in AL amyloidosis (HELIOS-6): a randomized phase 3 trial
Sofia Ioannou
Momavotinib plus ropeginterferon alfa-2b in myelofibrosis with anemia: randomized phase 3 results of the HORIZON-3 trial
Dana Ben-David
Ph-like signatures predicts outcome in T-cell ALL
Frank Weiß
Early chimerism predicts outcome in patients with steroid-refractory acute graft-versus-host disease
Linda Peters
Ponavatinib plus inotuzumab ozogamicin in children with high-risk B-cell ALL: phase 1 results of the ZENITH-2 trial
Ji-woo Lim
Bcr::abl1 transcript levels predicts outcome in CML after two or more tyrosine kinase inhibitors
Johannes Bauer
Ibarodomide plus daratumumab, bortezomib, lenalidomide and dexamethasone in relapsed/refractory multiple myeloma after three prior lines: phase 1 results of the ZENITH-6 trial
Eyal Azoulay
Treatment patterns and survival in adults with Philadelphia chromosome-positive ALL: real-world data from the European ALL registry
Juan Gao
Prognostic value of platelet response in people with severe hemophilia A: results from BEACON-3
Tamás Horváth
Multi-omic characterization of immune reconstitution after bispecific antibodies in high-risk smoldering myeloma
David King
Efficacy and safety of ravotuzumab vedotin in older adults with secondary AML: primary analysis of the phase 3 VIKING-5 study
Raquel Molina
A digital symptom-monitoring program plus antifungal prophylaxis in patients receiving CAR T-cell therapy: randomized phase 2 results of the VIKING-9 trial
Laura Mitchell
Multi-omic characterization of epigenetic memory after infection in aged mice
Astrid Hansson
Validation of a federated learning platform for the diagnosis of myeloid neoplasms across 19 centers
Simone Rossi
Olorofim plus standard supportive care in older patients with hematologic cancers: randomized phase 2 results of the BEACON-7 trial
Paolo Bianco
Efficacy and safety of mezoridomide in relapsed/refractory multiple myeloma after three prior lines: primary analysis of the phase 1 HORIZON-3 study
Giuseppe Grasso
A federated learning platform compared with expert morphological review on routine blood counts in primary care: a prospective multicenter evaluation
Markus Bauer
Efficacy and safety of zelvudocel in T-cell ALL: primary analysis of the randomized phase 2 ALTITUDE-1 study
Can Öztürk
Lovotigene autotemcel plus busulfan myeloablation in patients with sickle cell disease treated with gene editing: phase 1 results of the BEACON-4 trial
Arjun Banerjee
Ascavinib versus nilotinib in CML after two or more tyrosine kinase inhibitors (ECLIPSE-8): a phase 2 trial
Frida Lindqvist
Ibrexitamab plus blinatumomab in relapsed B-cell precursor ALL: randomized phase 2 results of the CASCADE-7 trial
Wouter Bos
Ph-like signatures predicts outcome in T-cell ALL
Lena Friedrich
Health-related quality of life in newly diagnosed transplant-eligible multiple myeloma: a prospective dutch study
Aleksandra Krawczyk
A large language model assistant compared with standard diagnostic workup on multicenter flow cytometry datasets: a prospective multicenter evaluation
Alice Davies
Targeting platelet desialylation in bleeding and thrombotic disorders: preclinical evidence
Renata Carvalho
Luspaterpin versus azacitidine in higher-risk MDS (CASCADE-7): a randomized phase 2 trial
Ron Ben-David
Prognostic value of TET2 and DNMT3A clones in healthy donors: results from HORIZON-4
John Green
Prognostic value of TET2 and DNMT3A clones in human cord blood: results from HELIOS-1
Johanna Wolf
Treatment patterns and survival in therapy-related MDS: real-world data from the German MDS registry
George Morgan
Health-related quality of life in peripheral T-cell lymphoma: a prospective french study
Anja Keller
Targeting transfusion-related immunomodulation in transfusion practice: preclinical evidence
Grace Edwards
Efficacy and safety of odrolimab in mantle cell lymphoma after BTK inhibitor failure: primary analysis of the phase 1 SAGA-8 study
Ingrid Gustafsson
Navolatib plus hydroxyurea in myelofibrosis with anemia: randomized phase 3 results of the BEACON-1 trial
Ulrike Braun
Targeting lineage priming in early progenitors in normal and malignant hematopoiesis: preclinical evidence
Mette Andersen
Efactocog beta plus low-molecular-weight heparin in adults with immune thrombocytopenia: phase 2 results of the ATLAS-6 trial
Lukas Fischer
Prognostic value of cell-of-origin subtype in primary CNS lymphoma: results from HELIOS-1
Rachel Turner
Abl1 kinase domain mutations predicts outcome in newly diagnosed chronic-phase CML
Ana Marín
Treatment patterns and survival in cancer-associated venous thromboembolism: real-world data from the multinational hemostasis registry
Andrew Smith
Cmv reactivation predicts outcome in haploidentical transplant recipients
Javier Serrano
Real-world effectiveness of belosarib in adults undergoing allogeneic stem cell transplantation for AML: a multicenter international cohort
Ilaria De Luca
Health-related quality of life in classic Hodgkin lymphoma: a prospective british study
Reza Rahimi
Real-world effectiveness of pathogen-reduced platelets in blood donors: a multicenter spanish cohort
Robert Clark
Prognostic value of HSC quiescence markers in healthy donors: results from CASCADE-4
Hannah Kaiser
Sabrelimab plus erythropoiesis-stimulating agents in lower-risk MDS with transfusion-dependent anemia: phase 2 results of the ECLIPSE-4 trial
Bruno Silva
Targeting lineage switch after CD19-directed therapy in acute lymphoblastic leukemia (ALL): preclinical evidence
Xin Ma
Long-term outcomes of children with high-risk B-cell ALL treated with pediatric-inspired chemotherapy: a French registry study of 112 patients
Christina Braun
A federated learning platform compared with expert morphological review on bone marrow smears: a prospective multicenter evaluation
Mathieu Perrin
Nk-501 versus busulfan myeloablation in patients receiving CD19-directed CAR T-cell therapy (ECLIPSE-5): a randomized phase 2 trial
Stefanie Kaiser
Prognostic value of TET2 and DNMT3A clones in healthy donors: results from AURORA-7
Laura Schneider
Single-cell profiling reveals lineage priming in early progenitors in normal and malignant hematopoiesis
Stefanie Berger
Prognostic value of CALR mutations in myelofibrosis with anemia: results from TRIDENT-4
Francesco Parisi
Ravelinib versus dasatinib in CML after two or more tyrosine kinase inhibitors (AURORA-2): a phase 1 trial
Michał Kwiatkowski
Ighv mutational status predicts outcome in older patients with CLL and comorbidities
Alba Rubio
Validation of a large language model assistant for the diagnosis of myeloid neoplasms across 37 centers
Léa Dupont
Long-term outcomes of myelofibrosis with anemia treated with hydroxyurea: a Nordic registry study of 412 patients
Helena Lindberg
Zelvudocel plus busulfan myeloablation in recipients of allogeneic off-the-shelf CAR NK cells: phase 3 results of the CORONA-4 trial
Giuseppe Vitale
Validation of a federated learning platform for the diagnosis of myeloid neoplasms across 20 centers
Roberto Vitale
Spleen volume reduction predicts outcome in polycythemia vera
Heather Jackson
Odrolimab versus R-CHOP in peripheral T-cell lymphoma (CORONA-9): a phase 3 trial
John Allen
Efficacy and safety of menavostat in newly diagnosed AML patients ineligible for intensive chemotherapy: primary analysis of the phase 2 NORDLYS-9 study
Marek Krawczyk
Alloimmunization predicts outcome in blood donors
Tobias Fuchs
Real-world effectiveness of letermovir in patients receiving CAR T-cell therapy: a multicenter german cohort
Laura Smith
Momavotinib plus ruxolitinib in polycythemia vera: phase 1 results of the SAGA-1 trial
Sarah Schulz
Real-world effectiveness of rilvabrutinib in adults with immune thrombocytopenia: a multicenter spanish cohort
Marie Michel
A large language model assistant compared with expert morphological review on routine blood counts in primary care: a prospective multicenter evaluation
Ana Muñoz
Treatment patterns and survival in relapsed CLL after covalent BTK inhibitors: real-world data from the multinational CLL registry
Matteo De Luca
Treatment patterns and survival in chronic-phase CML in deep molecular response: real-world data from the Dutch CML registry
Alessandra Russo
Multi-omic characterization of treatment-free remission biology in CML after two or more tyrosine kinase inhibitors
Hao Sun
A large language model assistant compared with standard diagnostic workup on bone marrow smears: a prospective multicenter evaluation
Frederik Olsen
Validation of a federated learning platform for the diagnosis of myeloid neoplasms across 45 centers
Emir Mehmedović
Nelbrutinib versus ibrutinib in older patients with CLL and comorbidities (POLARIS-2): a phase 1b/2 trial
Simon White
Lovotigene autotemcel versus lymphodepletion with fludarabine and cyclophosphamide in patients with sickle cell disease treated with gene editing (ECLIPSE-6): a phase 1 trial
Emre Şahin
Momavotinib plus ropeginterferon alfa-2b in myelofibrosis after ruxolitinib failure: phase 1 results of the CASCADE-8 trial
Chloé Perrin
A deep-learning cytomorphology model compared with expert morphological review on bone marrow smears: a prospective multicenter evaluation
Anjali Iyer
Real-world effectiveness of letermovir in long-term survivors of childhood leukemia: a multicenter spanish cohort
Hélène Garcia
Multi-omic characterization of immune reconstitution after bispecific antibodies in relapsed/refractory multiple myeloma after three prior lines
Lotte Vermeulen
Targeting quiescent CML stem cells in chronic myeloid leukemia (CML): preclinical evidence
Eirik Haugen
Validation of a federated learning platform for early detection of acute leukemia across 18 centers
Andrew Carter
Multi-omic characterization of treatment burden in patients with invasive fungal infections
Pablo López
Linzotamab plus teclistamab in triple-class exposed myeloma: randomized phase 3 results of the HORIZON-3 trial
Federico Lombardi
Zelvudocel plus blinatumomab in relapsed B-cell precursor ALL: phase 1 results of the SAGA-3 trial
Mark Thompson
Marsatimab versus emicizumab prophylaxis in people with severe hemophilia A (BEACON-5): a phase 1 trial
Juan Chen
Long-term outcomes of older patients with CLL and comorbidities treated with ibrutinib: a Nordic registry study of 812 patients
Signe Møller
Brexalucel plus bendamustine and rituximab in relapsed or refractory large B-cell lymphoma: phase 2 results of the BEACON-4 trial
David Sánchez
Sabrelimab plus luspatercept in higher-risk MDS: phase 2 results of the HORIZON-4 trial
Anouk Dijkstra
Treatment patterns and survival in T-cell ALL: real-world data from the British ALL registry
Diego Sanz
Prognostic value of spleen volume reduction in myelofibrosis with anemia: results from ZENITH-9
Pavel Novotný
Targeting immune reconstitution after bispecific antibodies in multiple myeloma: preclinical evidence
Allison Smith
Targeting inflammatory aging of the stem cell niche in normal and malignant hematopoiesis: preclinical evidence
Adrián Ramírez
Targeting graft-versus-leukemia effect in allogeneic stem cell transplantation: preclinical evidence
Feng Wang
Multi-omic characterization of red cell storage lesion in patients undergoing cardiac surgery
Jian Wu
Prognostic value of vaso-occlusive crisis rate in pyruvate kinase deficiency: results from HORIZON-5
Frida Berg
Real-world effectiveness of pelarisib in JAK inhibitor-naive myelofibrosis: a multicenter german cohort
Anja Klein
Osiverol versus chronic transfusion in non-transfusion-dependent beta-thalassemia (AURORA-2): a phase 1b/2 trial
Clara Molina
Validation of a federated learning platform for early detection of acute leukemia across 62 centers
Julia Schröder
Long-term outcomes of blood donors treated with patient blood management: a Nordic registry study of 2105 patients
André Carvalho
Menavostat versus azacitidine in relapsed or refractory FLT3-mutated AML (HELIOS-6): a randomized phase 2 trial
Sophie Clarke
Long-term outcomes of newly diagnosed AML patients ineligible for intensive chemotherapy treated with decitabine: a Dutch registry study of 1240 patients
Emil Jonsson
Long-term outcomes of patients with antiphospholipid syndrome treated with direct oral anticoagulants: a international registry study of 231 patients
Aleksandra Zieliński
Early chimerism predicts outcome in adults undergoing allogeneic stem cell transplantation for AML
Anil Mehta
Treatment patterns and survival in patients with invasive fungal infections: real-world data from the multinational supportive care registry
Ashley Martin
Multi-omic characterization of BCR signalling rewiring in relapsed CLL after covalent BTK inhibitors
Avi Ofer
Real-world effectiveness of zelvudocel in adolescents and young adults with ALL: a multicenter nordic cohort
Fredrik Sandberg
Rusperatide plus ropeginterferon alfa-2b in polycythemia vera: phase 1b/2 results of the ARCTIC-6 trial
Selma Marković
Rusperatide plus ropeginterferon alfa-2b in JAK inhibitor-naive myelofibrosis: phase 3 results of the CORONA-1 trial
Lei Zhu
Treatment patterns and survival in fit patients with untreated CLL: real-world data from the French CLL registry
María Rodríguez
Ibrexitamab plus tyrosine kinase inhibitors in adults with Philadelphia chromosome-positive ALL: randomized phase 3 results of the ALTITUDE-6 trial
Maria Sjöberg
Real-world effectiveness of ponavatinib in adolescents and young adults with ALL: a multicenter british cohort
Raúl Vázquez
Ph-like signatures predicts outcome in T-cell ALL
Roberto Colombo
Health-related quality of life in older adults with secondary AML: a prospective multinational study
Lucie Bernard
Prognostic value of FLT3-ITD allelic ratio in older adults with secondary AML: results from TRIDENT-9
Erik Berg
Targeting tissue factor pathway regulation in bleeding and thrombotic disorders: preclinical evidence
Paweł Lewandowski
Validation of a deep-learning cytomorphology model for automated classification of bone marrow cells across 41 centers
Diego Delgado
Prognostic value of hemoglobin response in adults with sickle cell disease: results from HORIZON-6
Daniel Hall
Multi-omic characterization of bone marrow stromal support in newly diagnosed transplant-eligible multiple myeloma
Andrei Dumitru
Zelvudocel plus lymphodepletion with fludarabine and cyclophosphamide in patients receiving CD19-directed CAR T-cell therapy: randomized phase 2 results of the ZENITH-7 trial
Konstantinos Angelopoulos
Efficacy and safety of quelcitamab in older adults with secondary AML: primary analysis of the randomized phase 3 CORONA-2 study
Yuko Sasaki
Targeting gut epithelial injury in GVHD in allogeneic stem cell transplantation: preclinical evidence
Keiko Yamada
Ravelinib versus nilotinib in newly diagnosed chronic-phase CML (HELIOS-6): a randomized phase 3 trial
Stefan Vuković
Ph-like signatures predicts outcome in children with high-risk B-cell ALL
Jun Liu
Long-term outcomes of previously untreated follicular lymphoma treated with R-CHOP: a British registry study of 64 patients
Diego Rubio
Prognostic value of BCR::ABL1 transcript levels in CML after two or more tyrosine kinase inhibitors: results from NORDLYS-4
Carolin Möller
Real-world effectiveness of mitazovat in adults with sickle cell disease: a multicenter european cohort
Viktor Bengtsson
Treatment patterns and survival in classic Hodgkin lymphoma: real-world data from the European lymphoma registry
Franziska Fischer
Sabrelimab plus luspatercept in lower-risk MDS with transfusion-dependent anemia: randomized phase 2 results of the CORONA-9 trial
Kevin Harris
Ph-like signatures predicts outcome in relapsed B-cell precursor ALL
Adam Dąbrowski
Whole blood versus restrictive transfusion thresholds in patients with massive hemorrhage (SUMMIT-7): a phase 3 trial
Tone Andersen
High-risk cytogenetics predicts outcome in AL amyloidosis
Alexander Braun
Treatment patterns and survival in MDS with SF3B1 mutation: real-world data from the Italian MDS registry
Moritz Frank
Whole blood versus restrictive transfusion thresholds in patients undergoing cardiac surgery (ZENITH-2): a randomized phase 2 trial
Annemieke Kok
Treatment patterns and survival in blood donors: real-world data from the Nordic transfusion registry
Brian Campbell
Health-related quality of life in relapsed or refractory FLT3-mutated AML: a prospective european study
James Parker
Validation of a deep-learning cytomorphology model for automated classification of bone marrow cells across 45 centers
Pernille Olsen
Prognostic value of GPRC5D expression in AL amyloidosis: results from ALTITUDE-6
Rania Mahmoud
Efficacy and safety of letermovir in patients receiving CAR T-cell therapy: primary analysis of the randomized phase 3 CORONA-6 study
Wei Chen
Tozarinib versus decitabine in AML in first complete remission (HORIZON-3): a phase 2 trial
Alessandra Mariani
Targeting inflammatory aging of the stem cell niche in normal and malignant hematopoiesis: preclinical evidence
Ji-yeon Lim
Real-world effectiveness of rusperatide in essential thrombocythemia: a multicenter british cohort
Paula Ramírez
Efficacy and safety of cold-stored platelets in preterm neonates: primary analysis of the phase 2 PRISM-3 study
Kristina Eriksson
Health-related quality of life in myelofibrosis after ruxolitinib failure: a prospective italian study
Marta Wiśniewski
Long-term outcomes of older patients with CLL and comorbidities treated with venetoclax and obinutuzumab: a European registry study of 188 patients
Jun Yang
Mrd negativity after induction predicts outcome in children with high-risk B-cell ALL
Raluca Gheorghe
Health-related quality of life in patients undergoing cardiac surgery: a prospective multinational study
Thomas Henry
Prognostic value of frailty scores in long-term survivors of childhood leukemia: results from ARCTIC-5
Alexandre David
Ravotuzumab vedotin versus venetoclax and azacitidine in adults with newly diagnosed AML receiving intensive induction (ZENITH-3): a phase 2 trial
Ida Holm
Cd19 antigen loss predicts outcome in adolescents and young adults with ALL
Lorenzo Russo
Single-cell profiling reveals alloreactive T-cell expansion in allogeneic stem cell transplantation
Marie Dupont
Real-world effectiveness of pirvabrutinib in fit patients with untreated CLL: a multicenter international cohort
Sofia Angelopoulos
Treatment patterns and survival in treatment-naive CLL: real-world data from the British CLL registry
Arnaud Muller
Single-cell profiling reveals epigenetic memory after infection in normal and malignant hematopoiesis
Hannah Walker
Multi-omic characterization of clonal evolution at relapse in relapsed or refractory FLT3-mutated AML
Francesco Conti
Long-term outcomes of non-transfusion-dependent beta-thalassemia treated with hydroxyurea: a Spanish registry study of 188 patients
Alexander Schmitt
Prognostic value of platelet response in hemophilia B: results from CORONA-9
Marija Babić
Real-world effectiveness of whole blood in blood donors: a multicenter italian cohort
Philipp Neumann
Rusperatide plus ruxolitinib in essential thrombocythemia: phase 1 results of the CASCADE-9 trial
Daan van den Berg
Efficacy and safety of lovotigene autotemcel in patients with sickle cell disease treated with gene editing: primary analysis of the phase 1 PRISM-4 study
Lei Sun
Real-world effectiveness of corvalimab in relapsed B-cell precursor ALL: a multicenter spanish cohort
Anna Zając
Health-related quality of life in pyruvate kinase deficiency: a prospective european study
Yuki Inoue
Targeting T-cell exhaustion in CLL in chronic lymphocytic leukemia (CLL): preclinical evidence
Piotr Zieliński
Prognostic value of high molecular risk mutations in myelofibrosis with anemia: results from AURORA-3
Christopher Roberts
Bcma soluble levels predicts outcome in AL amyloidosis
Wouter Mulder
Real-world effectiveness of mezoridomide in high-risk smoldering myeloma: a multicenter dutch cohort
Óscar Torres
Multi-omic characterization of epigenetic memory after infection in patients with clonal hematopoiesis of indeterminate potential
Ilaria Colombo
Pirvabrutinib versus ibrutinib in CLL with del(17p) or TP53 mutation (ECLIPSE-8): a phase 1b/2 trial
Piotr Kozłowski
Efficacy and safety of a digital symptom-monitoring program in older patients with hematologic cancers: primary analysis of the phase 3 MERIDIAN-7 study
Anjali Nair
Efficacy and safety of belosarib in adults undergoing allogeneic stem cell transplantation for AML: primary analysis of the phase 3 VALOR-8 study
Olivier Robert
A large language model assistant compared with expert morphological review on multicenter flow cytometry datasets: a prospective multicenter evaluation
Panagiotis Oikonomou
Somatic mutation burden predicts outcome in therapy-related MDS
Koen Peters
Single-cell profiling reveals tissue factor pathway regulation in bleeding and thrombotic disorders
Thiago Carvalho
Long-term outcomes of newly diagnosed chronic-phase CML treated with nilotinib: a multinational registry study of 412 patients
Hassan Saleh
Efficacy and safety of talvetamab in AL amyloidosis: primary analysis of the phase 1 SAGA-8 study
Thomas Patel
Single-cell profiling reveals financial toxicity in hematologic malignancies
Sophie Kok
Targeting treatment-free remission biology in chronic myeloid leukemia (CML): preclinical evidence
Layla Najjar
Multi-omic characterization of lineage switch after CD19-directed therapy in adolescents and young adults with ALL
Jorge Castro
Long-term outcomes of transfusion-dependent beta-thalassemia treated with busulfan myeloablation: a Dutch registry study of 87 patients
Lucas Santos
Real-world effectiveness of rilvabrutinib in cancer-associated venous thromboembolism: a multicenter nordic cohort
Sophie Neumann
Efficacy and safety of a digital symptom-monitoring program in patients receiving CAR T-cell therapy: primary analysis of the phase 1b/2 MERIDIAN-7 study
Giuseppe Barbieri
Treatment patterns and survival in lower-risk MDS with transfusion-dependent anemia: real-world data from the international MDS registry
Elif Yıldırım
Treatment patterns and survival in patients with sickle cell disease treated with gene editing: real-world data from the German cell therapy registry
Melissa Scott
Prognostic value of CAR T expansion kinetics in patients with sickle cell disease treated with gene editing: results from SUMMIT-3
Matteo D'Angelo
Targeting alloreactive T-cell expansion in allogeneic stem cell transplantation: preclinical evidence
Elif Kaya
Treatment patterns and survival in transfusion-dependent beta-thalassemia: real-world data from the Italian cell therapy registry
Edward Roberts
Prognostic value of somatic mutation burden in therapy-related MDS: results from POLARIS-2
Silvia Rubio
Efficacy and safety of lirafenib in newly diagnosed AML patients ineligible for intensive chemotherapy: primary analysis of the phase 1 PRISM-6 study
John Jones
Long-term outcomes of fit patients with untreated CLL treated with ibrutinib: a European registry study of 412 patients
Yan Lin
Efficacy and safety of cold-stored platelets in patients with massive hemorrhage: primary analysis of the phase 3 POLARIS-7 study
David Muñoz
Lisarnetamab versus R-CHOP in previously untreated follicular lymphoma (ATLAS-5): a phase 3 trial
Bas van der Linden
Efficacy and safety of orvematinib in newly diagnosed chronic-phase CML: primary analysis of the phase 2 AURORA-8 study
Cristina Martínez
Pelarisib versus ropeginterferon alfa-2b in JAK inhibitor-naive myelofibrosis (ATLAS-1): a phase 3 trial
Astrid Jansson
Whole blood plus restrictive transfusion thresholds in patients with massive hemorrhage: randomized phase 3 results of the VIKING-6 trial
João Fernandes
Car t expansion kinetics predicts outcome in patients with sickle cell disease treated with gene editing
Pilar Ortiz
Hepcidin levels predicts outcome in non-transfusion-dependent beta-thalassemia
Georgia Oikonomou
Zelvudocel plus tyrosine kinase inhibitors in adults with Philadelphia chromosome-positive ALL: randomized phase 3 results of the SUMMIT-7 trial
Ana Costa
Health-related quality of life in relapsed B-cell precursor ALL: a prospective french study
Miriam Berger
Corvalimab versus blinatumomab in T-cell ALL (NORDLYS-3): a phase 1b/2 trial
Álvaro Ramos
Itovazumab versus post-transplant cyclophosphamide in patients with steroid-refractory acute graft-versus-host disease (CASCADE-5): a phase 1b/2 trial
Hélène Martin
Multi-omic characterization of epigenetic memory after infection in patients with clonal hematopoiesis of indeterminate potential
Lena Klein
Early chimerism predicts outcome in patients with steroid-refractory acute graft-versus-host disease
Niklas Karlsson
Validation of a federated learning platform for early detection of acute leukemia across 49 centers
Balázs Horváth
Multi-omic characterization of lineage priming in early progenitors in healthy donors
Jing Zhao
Targeting ineffective erythropoiesis in myelodysplastic syndromes (MDS): preclinical evidence
Anna Mancini
Pirvabrutinib versus ibrutinib in CLL with del(17p) or TP53 mutation (AURORA-6): a randomized phase 3 trial
Alice Harris
Brexalucel plus bendamustine and rituximab in classic Hodgkin lymphoma: phase 2 results of the POLARIS-7 trial
Eva Lehmann
Long-term outcomes of relapsed B-cell precursor ALL treated with tyrosine kinase inhibitors: a international registry study of 146 patients
Neta Katz
Prognostic value of platelet response in people with severe hemophilia A: results from TRIDENT-7
Larissa Santos
Single-cell profiling reveals lineage priming in early progenitors in normal and malignant hematopoiesis
Ruben de Graaf
Olorofim plus standard supportive care in patients receiving CAR T-cell therapy: phase 1b/2 results of the ZENITH-6 trial
Joshua Davis
Abl1 kinase domain mutations predicts outcome in newly diagnosed chronic-phase CML
Birgit Keller
Prognostic value of fetal hemoglobin in children with sickle cell disease in sub-Saharan Africa: results from AURORA-2
Oliver Thompson
Orvematinib plus imatinib in chronic-phase CML in deep molecular response: randomized phase 2 results of the ATLAS-5 trial
Alessandro Mariani
Long-term outcomes of older patients with CLL and comorbidities treated with venetoclax and obinutuzumab: a multinational registry study of 812 patients
Ioannis Papadakis
Targeting alloreactive T-cell expansion in allogeneic stem cell transplantation: preclinical evidence
Rubén Navarro
Single-cell profiling reveals epigenetic memory after infection in normal and malignant hematopoiesis
Lucy Harrison
Real-world effectiveness of zelvudocel in transfusion-dependent beta-thalassemia: a multicenter spanish cohort
Fatma Öztürk
Efficacy and safety of orvematinib in newly diagnosed chronic-phase CML: primary analysis of the phase 3 ZENITH-2 study
Chloé Thomas
Real-world effectiveness of ponavatinib in adults with Philadelphia chromosome-positive ALL: a multicenter european cohort
Benjamin Patel
Real-world effectiveness of pathogen-reduced platelets in preterm neonates: a multicenter dutch cohort
Anne Hansen
Anicavocel versus autologous stem cell transplantation in AL amyloidosis (HORIZON-7): a phase 1 trial
Emma de Jong
A large language model assistant compared with standard diagnostic workup on bone marrow smears: a prospective multicenter evaluation
Joshua Jackson
Multi-omic characterization of CD20 antigen loss after bispecifics in previously untreated follicular lymphoma
Lena Engström
Single-cell profiling reveals bone marrow stromal support in multiple myeloma
Maya Mor
Treatment patterns and survival in NPM1-mutated AML: real-world data from the Italian AML registry
Fatemeh Rezaei
Prognostic value of cytokine release syndrome grade in recipients of allogeneic off-the-shelf CAR NK cells: results from ATLAS-1
Ilaria Serra
Rusperatide versus ruxolitinib in JAK inhibitor-naive myelofibrosis (ZENITH-1): a phase 1 trial
Nuria Rubio
Efficacy and safety of nelbrutinib in older patients with CLL and comorbidities: primary analysis of the phase 3 ECLIPSE-1 study
Federica De Santis
Real-world effectiveness of rusperatide in myelofibrosis with anemia: a multicenter nordic cohort
Jessica Smith
Prognostic value of infection-related mortality in patients receiving CAR T-cell therapy: results from HORIZON-4
Álvaro Martínez
Quelcitamab plus cytarabine and daunorubicin in adults with newly diagnosed AML receiving intensive induction: phase 2 results of the TRIDENT-1 trial
Tereza Dvořák
Single-cell profiling reveals financial toxicity in hematologic malignancies
Søren Andersen
Vedotalimab versus anti-thymocyte globulin in patients with steroid-refractory acute graft-versus-host disease (SAGA-4): a phase 1 trial
Layla Hassan
Abelorimab versus direct oral anticoagulants in hemophilia B (CORONA-4): a phase 2 trial
Martina Veselý
Single-cell profiling reveals T-cell exhaustion in CLL in chronic lymphocytic leukemia (CLL)
Jonathan Hill
Real-world effectiveness of tamirodene in therapy-related MDS: a multicenter european cohort
Farhad Moradi
Targeting transfusion-related immunomodulation in transfusion practice: preclinical evidence
Shirin Karimi
Hepcidin levels predicts outcome in children with sickle cell disease in sub-Saharan Africa
Sergio Morales
Health-related quality of life in children with sickle cell disease in sub-Saharan Africa: a prospective british study
Alexander Harris
Efficacy and safety of efactocog beta in people with severe hemophilia A: primary analysis of the phase 3 ATLAS-1 study
Larissa Silva
High-risk cytogenetics predicts outcome in relapsed/refractory multiple myeloma after three prior lines
Daniel Klein
Real-world effectiveness of whole blood in preterm neonates: a multicenter nordic cohort
Elena Matei
Tovaclax versus venetoclax and obinutuzumab in CLL with del(17p) or TP53 mutation (CORONA-3): a phase 1b/2 trial
Hannah Johnson
Inflammatory memory predicts outcome in patients with clonal hematopoiesis of indeterminate potential
François Leroy
Treatment patterns and survival in recipients of allogeneic off-the-shelf CAR NK cells: real-world data from the British cell therapy registry
Lucie Veselý
Ascavinib versus nilotinib in CML after two or more tyrosine kinase inhibitors (CASCADE-3): a phase 3 trial
Mika Yamaguchi
Treatment patterns and survival in classic Hodgkin lymphoma: real-world data from the European lymphoma registry
Evelien Smits
Orvematinib plus dasatinib in chronic-phase CML in deep molecular response: phase 3 results of the HELIOS-1 trial
Merve Kurt
Belosarib versus anti-thymocyte globulin in haploidentical transplant recipients (ARCTIC-6): a phase 1 trial
Layla Saad
Multi-omic characterization of clonal dominance in higher-risk MDS
Péter Tóth
Real-world effectiveness of lirafenib in adults with newly diagnosed AML receiving intensive induction: a multicenter nordic cohort
Maria Theodorou
Abl1 kinase domain mutations predicts outcome in chronic-phase CML in deep molecular response
Charlotte Clark
Multi-omic characterization of bone marrow stromal support in high-risk smoldering myeloma
Francesco Moretti
Targeting endothelial activation in hemoglobinopathies: preclinical evidence
Johanna Laine
Pathogen-reduced platelets plus restrictive transfusion thresholds in patients undergoing cardiac surgery: phase 1 results of the SAGA-5 trial
Niklas Gustafsson
Prognostic value of infection-related mortality in patients receiving CAR T-cell therapy: results from ALTITUDE-7
Linnea Pettersson
Real-world effectiveness of pelarisib in myelofibrosis with anemia: a multicenter french cohort
Helena Olsson
Long-term outcomes of fit patients with untreated CLL treated with acalabrutinib: a French registry study of 304 patients
Grace Davies
Prognostic value of cytokine release syndrome grade in patients with sickle cell disease treated with gene editing: results from POLARIS-8
Scott Johnson
Single-cell profiling reveals lineage priming in early progenitors in normal and malignant hematopoiesis
Alejandro Navarro
Prognostic value of IPSS-M risk category in lower-risk MDS with transfusion-dependent anemia: results from VALOR-4
Ewa Kaczmarek
Frailty scores predicts outcome in long-term survivors of childhood leukemia
Grace Campbell
Ascavinib plus nilotinib in newly diagnosed chronic-phase CML: phase 1 results of the BEACON-2 trial
Sanne de Jong
Inclazumab versus hydroxyurea in non-transfusion-dependent beta-thalassemia (AURORA-1): a phase 2 trial
Megan Harris
Pirvabrutinib plus acalabrutinib in treatment-naive CLL: phase 3 results of the VIKING-6 trial
Daniel Phillips
Treatment patterns and survival in therapy-related MDS: real-world data from the Dutch MDS registry
Mohamed Khoury
Single-cell profiling reveals inflammatory aging of the stem cell niche in normal and malignant hematopoiesis
Aurélie Henry
Single-cell profiling reveals gut epithelial injury in GVHD in allogeneic stem cell transplantation
Vincent Perrin
Efficacy and safety of orvematinib in CML after two or more tyrosine kinase inhibitors: primary analysis of the phase 1b/2 POLARIS-3 study
Ying Lin
Efficacy and safety of orvematinib in chronic-phase CML in deep molecular response: primary analysis of the phase 2 POLARIS-4 study
Élodie Guerin
Cd19 antigen loss predicts outcome in adolescents and young adults with ALL
Mihai Dumitru
Real-world effectiveness of navolatib in myelofibrosis after ruxolitinib failure: a multicenter spanish cohort
Edward Morris
Health-related quality of life in older adults with secondary AML: a prospective spanish study
Hugo Jesus
Treatment patterns and survival in chronic-phase CML in deep molecular response: real-world data from the Dutch CML registry
Davide Barbieri
Whole blood plus restrictive transfusion thresholds in preterm neonates: phase 3 results of the AURORA-5 trial
María Castro
Single-cell profiling reveals iron overload and oxidative stress in hemoglobinopathies
Ingrid Mulder
Efficacy and safety of tamirodene in higher-risk MDS: primary analysis of the phase 1b/2 CORONA-3 study
Arnaud Martinez
Orvematinib versus dasatinib in CML after two or more tyrosine kinase inhibitors (CASCADE-6): a phase 1 trial
Daan van Dijk
Multi-omic characterization of metabolic rewiring under BCL-2 inhibition in newly diagnosed AML patients ineligible for intensive chemotherapy
Per Svensson
Validation of a federated learning platform for automated classification of bone marrow cells across 22 centers
Marko Tomić
Health-related quality of life in CML after two or more tyrosine kinase inhibitors: a prospective european study
Margaux Guerin
Targeting bone marrow stromal support in multiple myeloma: preclinical evidence
Paola Colombo
Targeting red cell storage lesion in transfusion practice: preclinical evidence
Johannes Schwarz
Treatment patterns and survival in cancer-associated venous thromboembolism: real-world data from the Italian hemostasis registry
Erik Andersson
Real-world effectiveness of ravelinib in CML after two or more tyrosine kinase inhibitors: a multicenter british cohort
Eleanor Jones
Long-term outcomes of older adults with secondary AML treated with azacitidine: a Dutch registry study of 58 patients
Andrea Lehmann
Single-cell profiling reveals inflammatory aging of the stem cell niche in normal and malignant hematopoiesis
Stefan Scholz
Efficacy and safety of quelcitamab in NPM1-mutated AML: primary analysis of the randomized phase 2 SUMMIT-9 study
Christian Schwarz
Epretamab plus bendamustine and rituximab in mantle cell lymphoma after BTK inhibitor failure: phase 2 results of the NORDLYS-5 trial
Takeshi Tanaka
Prognostic value of high-risk cytogenetics in triple-class exposed myeloma: results from CORONA-1
Ivan Begić
Long-term outcomes of patients with invasive fungal infections treated with antifungal prophylaxis: a French registry study of 112 patients
Jan Beck
Efficacy and safety of efactocog beta in adults with immune thrombocytopenia: primary analysis of the randomized phase 3 AURORA-1 study
Tobias Hofmann
Long-term outcomes of triple-class exposed myeloma treated with daratumumab, bortezomib, lenalidomide and dexamethasone: a British registry study of 58 patients
Allison Thompson
Efficacy and safety of mitazovat in adults with sickle cell disease: primary analysis of the randomized phase 3 ALTITUDE-8 study
Diego Suárez
Prognostic value of GPRC5D expression in newly diagnosed transplant-eligible multiple myeloma: results from VIKING-7
Julia Carter
Long-term outcomes of older patients with hematologic cancers treated with standard supportive care: a French registry study of 812 patients
Silvia Rodríguez
Olorofim versus antifungal prophylaxis in older patients with hematologic cancers (SAGA-4): a phase 1 trial
Esther de Jong
A deep-learning cytomorphology model compared with expert morphological review on bone marrow smears: a prospective multicenter evaluation
Maya Cohen
Health-related quality of life in T-cell ALL: a prospective german study
Stefanie Möller
Validation of a large language model assistant for the diagnosis of myeloid neoplasms across 29 centers
Linda Janssen
Long-term outcomes of adults undergoing allogeneic stem cell transplantation for AML treated with post-transplant cyclophosphamide: a Nordic registry study of 586 patients
Alexander Hughes
Treatment patterns and survival in newly diagnosed chronic-phase CML: real-world data from the multinational CML registry
Sophie Cooper
Efficacy and safety of tovaclax in relapsed CLL after covalent BTK inhibitors: primary analysis of the phase 2 SAGA-6 study
Sébastien Henry
Lirafenib plus decitabine in older adults with secondary AML: phase 2 results of the NORDLYS-6 trial
Amelia Bennett
Prognostic value of vector copy number in recipients of allogeneic off-the-shelf CAR NK cells: results from MERIDIAN-9
Wolfgang Weber
A deep-learning cytomorphology model compared with standard diagnostic workup on multicenter flow cytometry datasets: a prospective multicenter evaluation
Federico Gallo
Jak2 v617f allele burden predicts outcome in essential thrombocythemia
Giovanni De Luca
Single-cell profiling reveals lineage priming in early progenitors in normal and malignant hematopoiesis
Tim Vos
Real-world effectiveness of exacatogene autotemcel in recipients of allogeneic off-the-shelf CAR NK cells: a multicenter nordic cohort
Pauline Laurent
Frailty scores predicts outcome in patients receiving CAR T-cell therapy
Emil Karlsson
Glovutamab versus bendamustine and rituximab in mantle cell lymphoma after BTK inhibitor failure (CORONA-1): a randomized phase 2 trial
Emi Takahashi
Targeting epigenetic memory after infection in normal and malignant hematopoiesis: preclinical evidence
Rebecca Baker
Validation of a federated learning platform for early detection of acute leukemia across 13 centers
Fredrik Engström
Efficacy and safety of linzotamab in high-risk smoldering myeloma: primary analysis of the phase 2 TRIDENT-2 study
Gil Shalom
Multi-omic characterization of inflammatory aging of the stem cell niche in patients with clonal hematopoiesis of indeterminate potential
Claudia Frank
Platelet response predicts outcome in adults with immune thrombocytopenia
Akiko Nakamura
D-dimer predicts outcome in people with severe hemophilia A
Kevin Brown
Prognostic value of TP53 multi-hit status in higher-risk MDS: results from TRIDENT-2
Paolo Martinelli
Prognostic value of alloimmunization in preterm neonates: results from BEACON-5
Yong Guo
Calr mutations predicts outcome in JAK inhibitor-naive myelofibrosis
Claire Jackson
Telvostat plus luspatercept in therapy-related MDS: phase 1b/2 results of the ZENITH-6 trial
Sarah Mitchell
Mezoridomide plus teclistamab in triple-class exposed myeloma: phase 2 results of the MERIDIAN-2 trial
Mattias Johansson
Odrolimab versus R-CHOP in peripheral T-cell lymphoma (CASCADE-7): a randomized phase 2 trial
Andrew Harrison
Treatment patterns and survival in recipients of allogeneic off-the-shelf CAR NK cells: real-world data from the Spanish cell therapy registry
Yuko Nakamura
Multi-omic characterization of steroid resistance pathways in relapsed B-cell precursor ALL
Eva Koch
Efficacy and safety of menavostat in relapsed or refractory FLT3-mutated AML: primary analysis of the phase 1 SAGA-3 study
Johannes Günther
Cd19 antigen loss predicts outcome in adults with Philadelphia chromosome-positive ALL
Clément Lambert
Efficacy and safety of ibarodomide in triple-class exposed myeloma: primary analysis of the phase 1b/2 NORDLYS-2 study
Oliver Taylor
Prognostic value of inflammatory memory in healthy donors: results from SAGA-3
Aurélie Legrand
Single-cell profiling reveals lineage priming in early progenitors in normal and malignant hematopoiesis
Pietro Marchetti
Long-term outcomes of essential thrombocythemia treated with hydroxyurea: a multinational registry study of 586 patients
Nicole Clark
Vaso-occlusive crisis rate predicts outcome in pyruvate kinase deficiency
Koji Ito
Prognostic value of patient-reported outcomes in patients with invasive fungal infections: results from ATLAS-2
Fredrik Lindqvist
Tet2 and dnmt3a clones predicts outcome in patients with clonal hematopoiesis of indeterminate potential
Katherine Baker
Real-world effectiveness of luspaterpin in higher-risk MDS: a multicenter german cohort
Mette Christensen
Prognostic value of ferritin in donors in patients with massive hemorrhage: results from TRIDENT-9
Rania Saleh
Bcma soluble levels predicts outcome in triple-class exposed myeloma
Elizabeth Wilson
Odrolimab versus bendamustine and rituximab in previously untreated follicular lymphoma (ECLIPSE-6): a randomized phase 3 trial
Franziska Hoffmann
Olorofim versus standard supportive care in patients receiving CAR T-cell therapy (POLARIS-6): a phase 1b/2 trial
Takeshi Sato
Long-term outcomes of AL amyloidosis treated with teclistamab: a French registry study of 812 patients
Oskar Larsson
Targeting gut epithelial injury in GVHD in allogeneic stem cell transplantation: preclinical evidence
Ying Ma
Glovutamab versus CAR T-cell therapy in classic Hodgkin lymphoma (SAGA-6): a phase 2 trial
Stephanie Harris
Single-cell profiling reveals endothelial activation in hemoglobinopathies
Paolo Ferraro
A deep-learning cytomorphology model compared with standard diagnostic workup on patients with suspected myeloid neoplasms: a prospective multicenter evaluation
Rania Najjar
Efficacy and safety of olorofim in long-term survivors of childhood leukemia: primary analysis of the phase 1b/2 PRISM-2 study
Pierre Mercier
Real-world effectiveness of olorofim in long-term survivors of childhood leukemia: a multicenter dutch cohort
Emi Yamada
Prognostic value of high-risk cytogenetics in relapsed/refractory multiple myeloma after three prior lines: results from CORONA-2
George Shaw
Efficacy and safety of ascavinib in newly diagnosed chronic-phase CML: primary analysis of the phase 1b/2 PRISM-7 study
Andreas Schwarz
Multi-omic characterization of epigenetic memory after infection in human cord blood
Mona Hassan
Tamirodene plus azacitidine in higher-risk MDS: phase 1 results of the PRISM-9 trial
Sven Eriksson
Multi-omic characterization of iron overload and oxidative stress in patients with iron deficiency anemia
Silvia Gutiérrez
Efficacy and safety of a digital symptom-monitoring program in patients receiving CAR T-cell therapy: primary analysis of the randomized phase 2 SUMMIT-6 study
Konstantinos Pappas
Targeting CD20 antigen loss after bispecifics in lymphoma: preclinical evidence
Nikolaos Christodoulou
Real-world effectiveness of orvematinib in newly diagnosed chronic-phase CML: a multicenter british cohort
Pietro Conti
Treatment patterns and survival in MDS with SF3B1 mutation: real-world data from the Dutch MDS registry
George Walker
Treatment patterns and survival in relapsed or refractory large B-cell lymphoma: real-world data from the German lymphoma registry
Tomáš Novák
Efficacy and safety of sabrelimab in therapy-related MDS: primary analysis of the phase 1 HORIZON-9 study
Karim Najjar
A deep-learning cytomorphology model compared with expert morphological review on bone marrow smears: a prospective multicenter evaluation
Laura Winkler
Targeting inflammatory aging of the stem cell niche in normal and malignant hematopoiesis: preclinical evidence
Markus Lange
Treatment patterns and survival in newly diagnosed chronic-phase CML: real-world data from the multinational CML registry
Anna Smirnov
Treatment patterns and survival in chronic-phase CML in deep molecular response: real-world data from the Italian CML registry
Andrea Parisi
Targeting tumour microenvironment remodelling in lymphoma: preclinical evidence
Yu Guo
Epretamab versus Pola-R-CHP in previously untreated follicular lymphoma (SAGA-9): a randomized phase 3 trial
Johanna Schmitt
Anicavocel versus autologous stem cell transplantation in triple-class exposed myeloma (POLARIS-1): a phase 3 trial
Elena Rodríguez
Single-cell profiling reveals bone marrow stromal support in multiple myeloma
Luis Iglesias
Prognostic value of platelet count increment in preterm neonates: results from CORONA-2
Hala Farouk
Orvematinib plus imatinib in CML after two or more tyrosine kinase inhibitors: phase 1b/2 results of the SUMMIT-8 trial
Mona Farouk
Long-term outcomes of patients receiving CAR T-cell therapy treated with standard supportive care: a Spanish registry study of 64 patients
Franziska Weiß
Targeting Richter transformation in chronic lymphocytic leukemia (CLL): preclinical evidence
Anouk Dekker
Real-world effectiveness of mitazovat in patients with iron deficiency anemia: a multicenter german cohort
Jian Luo
Treatment patterns and survival in lower-risk MDS with transfusion-dependent anemia: real-world data from the Nordic MDS registry
Margaux Moreau
Epretamab plus bendamustine and rituximab in relapsed or refractory large B-cell lymphoma: randomized phase 2 results of the POLARIS-1 trial
Andrew Baker
Efficacy and safety of corvalimab in relapsed B-cell precursor ALL: primary analysis of the randomized phase 2 VALOR-6 study
Thomas Mercier
A deep-learning cytomorphology model compared with expert morphological review on routine blood counts in primary care: a prospective multicenter evaluation
Deniz Aslan
Fetal hemoglobin predicts outcome in adults with sickle cell disease
Markus Köhler
D-dimer predicts outcome in adults with immune thrombocytopenia
Alexandre François
Real-world effectiveness of lirafenib in relapsed or refractory FLT3-mutated AML: a multicenter european cohort
Ruben Smits
Real-world effectiveness of odrolimab in primary CNS lymphoma: a multicenter european cohort
Romain Nicolas
Prognostic value of high-risk cytogenetics in triple-class exposed myeloma: results from TRIDENT-8
Lea Scholz
Prognostic value of undetectable MRD in older patients with CLL and comorbidities: results from ZENITH-5
Antonio Blanco
Efficacy and safety of concivumab in adults with immune thrombocytopenia: primary analysis of the phase 3 AURORA-3 study
Henrik Axelsson
Single-cell profiling reveals thrombosis in MPN in myeloproliferative neoplasms (MPN)
Allison Nguyen
Cd19 antigen loss predicts outcome in children with high-risk B-cell ALL
Sergio Gómez
Inclazumab plus iron chelation in pyruvate kinase deficiency: randomized phase 2 results of the ECLIPSE-4 trial
Karim Hassan
Health-related quality of life in older patients with CLL and comorbidities: a prospective multinational study
Elena Romano
Validation of a federated learning platform for the diagnosis of myeloid neoplasms across 26 centers
Rubén Ortega
Belosarib plus tacrolimus and methotrexate in patients with steroid-refractory acute graft-versus-host disease: phase 3 results of the ARCTIC-1 trial
Daniel Schmidt
Zelvudocel versus pediatric-inspired chemotherapy in relapsed B-cell precursor ALL (NORDLYS-2): a phase 3 trial
Beatriz Torres
Itovazumab plus tacrolimus and methotrexate in haploidentical transplant recipients: phase 1b/2 results of the ATLAS-4 trial
Rachel Scott
Multi-omic characterization of neutrophil extracellular traps in thrombosis in cancer-associated venous thromboembolism
Chiara Barbieri
Multi-omic characterization of neutrophil extracellular traps in thrombosis in adults with immune thrombocytopenia
Kristina Engström
Long-term outcomes of previously untreated follicular lymphoma treated with R-CHOP: a international registry study of 812 patients
Markus Wolf
Real-world effectiveness of nelbrutinib in older patients with CLL and comorbidities: a multicenter multinational cohort
Francesca De Santis
Efficacy and safety of orvematinib in CML after two or more tyrosine kinase inhibitors: primary analysis of the phase 3 ZENITH-7 study
Balázs Farkas
Osiverol plus chronic transfusion in patients with iron deficiency anemia: randomized phase 2 results of the VIKING-4 trial
Davide Esposito
Efficacy and safety of ibrexitamab in relapsed B-cell precursor ALL: primary analysis of the randomized phase 2 HORIZON-9 study
Patricia Ortega
Cold-stored platelets plus restrictive transfusion thresholds in blood donors: phase 3 results of the SAGA-6 trial
Helena Gustafsson
Real-world effectiveness of whole blood in patients undergoing cardiac surgery: a multicenter french cohort
Carmen Suárez
Real-world effectiveness of marsatimab in patients with antiphospholipid syndrome: a multicenter french cohort
Joost de Graaf
Real-world effectiveness of cold-stored platelets in patients undergoing cardiac surgery: a multicenter spanish cohort
Diana Ionescu
Validation of a large language model assistant for early detection of acute leukemia across 40 centers
Ida Solberg
Tp53 multi-hit status predicts outcome in MDS with SF3B1 mutation
Ulrike Winkler
Mrd negativity at 10^-6 predicts outcome in relapsed/refractory multiple myeloma after three prior lines
Neha Singh
Prognostic value of platelet count increment in patients undergoing cardiac surgery: results from TRIDENT-7
Ioannis Nikolaidis
Ibrexitamab versus pediatric-inspired chemotherapy in children with high-risk B-cell ALL (SAGA-9): a phase 1b/2 trial
Davide Ferri
Single-cell profiling reveals treatment-free remission biology in chronic myeloid leukemia (CML)
Nuno Martins
Prognostic value of inflammatory memory in aged mice: results from ATLAS-2
Hassan Hamdan
Targeting clonal evolution under BCMA pressure in multiple myeloma: preclinical evidence
Oliver Green
Abl1 kinase domain mutations predicts outcome in newly diagnosed chronic-phase CML
Min-seo Choi
Targeting transfusion-related immunomodulation in transfusion practice: preclinical evidence
Rocío Torres
Long-term outcomes of older adults with secondary AML treated with cytarabine and daunorubicin: a international registry study of 146 patients
Divya Banerjee
Single-cell profiling reveals metabolic rewiring under BCL-2 inhibition in acute myeloid leukemia (AML)
Amelia Harris
Real-world effectiveness of vedotalimab in patients with steroid-refractory acute graft-versus-host disease: a multicenter nordic cohort
Péter Nagy
Treatment patterns and survival in non-transfusion-dependent beta-thalassemia: real-world data from the Nordic SCD registry
Juan He
Single-cell profiling reveals inflammatory aging of the stem cell niche in normal and malignant hematopoiesis
Ashley Green
Validation of a deep-learning cytomorphology model for the diagnosis of myeloid neoplasms across 16 centers
Mariana Gomes
Prognostic value of MRD negativity at 10^-6 in newly diagnosed transplant-eligible multiple myeloma: results from VIKING-4
Ingrid Johansson
Prognostic value of BCR::ABL1 transcript levels in newly diagnosed chronic-phase CML: results from ATLAS-8
Bogdan Ciobanu
Single-cell profiling reveals clonal evolution at relapse in acute myeloid leukemia (AML)
Laura Meier
Long-term outcomes of triple-class exposed myeloma treated with daratumumab, bortezomib, lenalidomide and dexamethasone: a Nordic registry study of 304 patients
Étienne Morel
Real-world effectiveness of a digital symptom-monitoring program in patients receiving CAR T-cell therapy: a multicenter german cohort
Lorenzo Santoro
Real-world effectiveness of epretamab in previously untreated follicular lymphoma: a multicenter multinational cohort
Johannes Weiß
Epretamab plus bendamustine and rituximab in peripheral T-cell lymphoma: randomized phase 2 results of the ECLIPSE-9 trial
Beatriz Gonçalves
Efficacy and safety of pelarisib in essential thrombocythemia: primary analysis of the phase 3 PRISM-3 study
Rita Carvalho
Single-cell profiling reveals Richter transformation in chronic lymphocytic leukemia (CLL)
Miriam Friedrich
Long-term outcomes of newly diagnosed chronic-phase CML treated with imatinib: a Dutch registry study of 586 patients
Alice Brown
Efficacy and safety of concivumab in people with severe hemophilia A: primary analysis of the randomized phase 2 SUMMIT-3 study
Lea Friedrich
Navolatib plus ruxolitinib in JAK inhibitor-naive myelofibrosis: randomized phase 3 results of the TRIDENT-2 trial
Rahul Joshi
Treatment patterns and survival in adults with sickle cell disease: real-world data from the British SCD registry
Dina Saleh
Prognostic value of undetectable MRD in CLL with del(17p) or TP53 mutation: results from SAGA-4
Priya Kumar
Real-world effectiveness of tamirodene in lower-risk MDS with transfusion-dependent anemia: a multicenter british cohort
Lauren Campbell
Prognostic value of IPSS-M risk category in MDS with SF3B1 mutation: results from ALTITUDE-4
William Robinson
Targeting epigenetic memory after infection in normal and malignant hematopoiesis: preclinical evidence
Julie Nicolas
Vector copy number predicts outcome in patients with sickle cell disease treated with gene editing
Lakshmi Chatterjee
Real-world effectiveness of odrolimab in peripheral T-cell lymphoma: a multicenter dutch cohort
Mathilde Nicolas
Single-cell profiling reveals graft-versus-leukemia effect in allogeneic stem cell transplantation
Merve Öztürk
Rusperatide plus ruxolitinib in polycythemia vera: phase 1 results of the ATLAS-1 trial
Xin Hu
Multi-omic characterization of inflammatory cytokine signalling in essential thrombocythemia
Mikkel Andersen
Odrolimab plus Pola-R-CHP in primary CNS lymphoma: phase 1 results of the POLARIS-4 trial
Bruno Martins
Ph-like signatures predicts outcome in adolescents and young adults with ALL
James Miller
Targeting treatment-free remission biology in chronic myeloid leukemia (CML): preclinical evidence
Elisa Parisi
Navolatib plus ropeginterferon alfa-2b in myelofibrosis with anemia: randomized phase 2 results of the VIKING-6 trial
Linda van der Meer
Zelvudocel versus tyrosine kinase inhibitors in adults with Philadelphia chromosome-positive ALL (CORONA-7): a phase 2 trial
Amit Mehta
Bcma soluble levels predicts outcome in AL amyloidosis
Ida Wallin
Sabrelimab plus azacitidine in lower-risk MDS with transfusion-dependent anemia: phase 3 results of the VALOR-5 trial
Andrea Günther
Validation of a deep-learning cytomorphology model for the diagnosis of myeloid neoplasms across 56 centers
Anna Németh
Prognostic value of hepcidin levels in pyruvate kinase deficiency: results from NORDLYS-3
Álvaro Ramírez
Prognostic value of inflammatory memory in healthy donors: results from ATLAS-6
Kari Strand
Long-term outcomes of people with severe hemophilia A treated with low-molecular-weight heparin: a Spanish registry study of 231 patients
Victoria Thompson
Efficacy and safety of itovazumab in haploidentical transplant recipients: primary analysis of the phase 1 MERIDIAN-3 study
Xiaoyan Zhou
Cell-of-origin subtype predicts outcome in classic Hodgkin lymphoma
Fernando Díaz
Rilvabrutinib versus thrombopoietin receptor agonists in hemophilia B (MERIDIAN-4): a phase 1b/2 trial
Sung-min Yoon
Single-cell profiling reveals CAR T-cell exhaustion in gene and cell therapy
Patricia Sánchez
Real-world effectiveness of mezoridomide in AL amyloidosis: a multicenter french cohort
Miriam Lange
Single-cell profiling reveals ineffective erythropoiesis in myelodysplastic syndromes (MDS)
Pietro Coppola
Linzotamab versus daratumumab, bortezomib, lenalidomide and dexamethasone in high-risk smoldering myeloma (AURORA-1): a phase 3 trial
Silvia Caruso
Health-related quality of life in patients receiving CAR T-cell therapy: a prospective italian study
Liang Zhu
Prognostic value of HSC quiescence markers in human cord blood: results from SUMMIT-9
Fredrik Holm
Long-term outcomes of pyruvate kinase deficiency treated with chronic transfusion: a multinational registry study of 112 patients
Theresa Fischer
Real-world effectiveness of cold-stored platelets in patients undergoing cardiac surgery: a multicenter international cohort
Yan Xu
Real-world effectiveness of glovutamab in mantle cell lymphoma after BTK inhibitor failure: a multicenter spanish cohort
Sander de Groot
Targeting immune evasion in the bone marrow niche in acute myeloid leukemia (AML): preclinical evidence
Lucie Martinez
Treatment patterns and survival in triple-class exposed myeloma: real-world data from the multinational myeloma registry
Valentina Grasso
Efficacy and safety of mitazovat in pyruvate kinase deficiency: primary analysis of the phase 1b/2 PRISM-3 study
Mikkel Sørensen
Real-world effectiveness of odrolimab in peripheral T-cell lymphoma: a multicenter multinational cohort
Pablo Rubio
Efficacy and safety of itovazumab in older recipients of reduced-intensity conditioning: primary analysis of the phase 2 TRIDENT-2 study
Lucy Roberts
Fetal hemoglobin induction predicts outcome in patients receiving CD19-directed CAR T-cell therapy
Lea Roth
Treatment patterns and survival in patients with steroid-refractory acute graft-versus-host disease: real-world data from the Italian allo-HSCT registry
Anouk Jansen
Targeting lineage priming in early progenitors in normal and malignant hematopoiesis: preclinical evidence
Benjamin Moore
Real-world effectiveness of NK-501 in recipients of allogeneic off-the-shelf CAR NK cells: a multicenter european cohort
Lena Fuchs
Prognostic value of MRD negativity at 10^-6 in relapsed/refractory multiple myeloma after three prior lines: results from SAGA-2
Iván García
Mrd negativity after induction predicts outcome in relapsed B-cell precursor ALL
Linnea Lundberg
Single-cell profiling reveals lineage priming in early progenitors in normal and malignant hematopoiesis
Petr Veselý
Efficacy and safety of itovazumab in patients with steroid-refractory acute graft-versus-host disease: primary analysis of the randomized phase 3 VIKING-3 study
Kimberly Green
Efficacy and safety of corvalimab in T-cell ALL: primary analysis of the randomized phase 3 SUMMIT-7 study
Giuseppe Rinaldi
Long-term outcomes of recipients of allogeneic off-the-shelf CAR NK cells treated with busulfan myeloablation: a British registry study of 58 patients
Signe Knudsen
Real-world effectiveness of efactocog beta in cancer-associated venous thromboembolism: a multicenter dutch cohort
Chen Wang
Efficacy and safety of etapivat in children with sickle cell disease in sub-Saharan Africa: primary analysis of the phase 1 HORIZON-7 study
Rik Dijkstra
Targeting gut epithelial injury in GVHD in allogeneic stem cell transplantation: preclinical evidence
Alessandro Parisi
Treatment patterns and survival in primary CNS lymphoma: real-world data from the Nordic lymphoma registry
Maarten de Graaf
Health-related quality of life in cancer-associated venous thromboembolism: a prospective international study
Ilaria Marchetti
Treatment patterns and survival in JAK inhibitor-naive myelofibrosis: real-world data from the Dutch MPN registry
Stefano Barbieri
Targeting CAR T-cell exhaustion in gene and cell therapy: preclinical evidence
Elina Hämäläinen
Momavotinib plus ropeginterferon alfa-2b in JAK inhibitor-naive myelofibrosis: phase 1b/2 results of the NORDLYS-4 trial
Bogdan Dumitru
Long-term outcomes of relapsed or refractory FLT3-mutated AML treated with venetoclax and azacitidine: a multinational registry study of 64 patients
Catarina Alves
Real-world effectiveness of letermovir in long-term survivors of childhood leukemia: a multicenter spanish cohort
Tarek Aziz
Validation of a federated learning platform for automated classification of bone marrow cells across 21 centers
Thomas Harris
Single-cell profiling reveals lineage priming in early progenitors in normal and malignant hematopoiesis
Jun Guo
Multi-omic characterization of lineage switch after CD19-directed therapy in adolescents and young adults with ALL
Petar Petrović
Prognostic value of microbiome diversity in haploidentical transplant recipients: results from SUMMIT-9
Adrián Pérez
Health-related quality of life in newly diagnosed AML patients ineligible for intensive chemotherapy: a prospective multinational study
Silvia Mariani
Real-world effectiveness of sabrelimab in higher-risk MDS: a multicenter dutch cohort
Clara Delgado
Real-world effectiveness of lisarnetamab in classic Hodgkin lymphoma: a multicenter british cohort
María Ramírez
Treatment patterns and survival in peripheral T-cell lymphoma: real-world data from the international lymphoma registry
Ji-ho Kang
Cell-of-origin subtype predicts outcome in peripheral T-cell lymphoma
Mathieu Rousseau
Efficacy and safety of marsatimab in cancer-associated venous thromboembolism: primary analysis of the phase 3 ARCTIC-2 study
Petra Veselý
Real-world effectiveness of efactocog beta in hemophilia B: a multicenter french cohort
Frank Roth
Efficacy and safety of zelvudocel in transfusion-dependent beta-thalassemia: primary analysis of the phase 1 VIKING-2 study
Victoria Bennett
Targeting endothelial activation in hemoglobinopathies: preclinical evidence
Xiaoyan He
Ascavinib plus imatinib in chronic-phase CML in deep molecular response: phase 1 results of the MERIDIAN-1 trial
Oskar Persson
Targeting lineage priming in early progenitors in normal and malignant hematopoiesis: preclinical evidence
Beatriz Serrano
Multi-omic characterization of tissue factor pathway regulation in adults with immune thrombocytopenia
Sergio Alonso
Validation of a large language model assistant for the diagnosis of myeloid neoplasms across 50 centers
Hiroshi Shimizu
Real-world effectiveness of epretamab in classic Hodgkin lymphoma: a multicenter british cohort
Joost Dijkstra
Validation of a large language model assistant for the diagnosis of myeloid neoplasms across 58 centers
Malin Persson
A deep-learning cytomorphology model compared with standard diagnostic workup on bone marrow smears: a prospective multicenter evaluation
Benjamin Morgan
Epretamab versus bendamustine and rituximab in relapsed or refractory large B-cell lymphoma (CASCADE-5): a phase 2 trial
Ida Knudsen
Targeting clonal dominance in myelodysplastic syndromes (MDS): preclinical evidence
Theresa Köhler
Health-related quality of life in fit patients with untreated CLL: a prospective international study
Dong-hyun Seo
Pathogen-reduced platelets plus patient blood management in patients with massive hemorrhage: phase 3 results of the ATLAS-6 trial
Roberto Rinaldi
Validation of a large language model assistant for early detection of acute leukemia across 33 centers
Camille Mercier
Treatment patterns and survival in AL amyloidosis: real-world data from the European myeloma registry
Miriam Fischer
Health-related quality of life in patients with antiphospholipid syndrome: a prospective dutch study
Bruno Oliveira
Real-world effectiveness of belosarib in adults undergoing allogeneic stem cell transplantation for AML: a multicenter french cohort
Yong Ma
Treatment patterns and survival in haploidentical transplant recipients: real-world data from the Italian allo-HSCT registry
Maxime Muller
Prognostic value of vaso-occlusive crisis rate in children with sickle cell disease in sub-Saharan Africa: results from SAGA-8
Sakura Yamaguchi
Ascavinib plus nilotinib in newly diagnosed chronic-phase CML: phase 1b/2 results of the AURORA-7 trial
Hugo Muller
Real-world effectiveness of sabrelimab in MDS with SF3B1 mutation: a multicenter spanish cohort
Sergio Marín
Treatment patterns and survival in CML after two or more tyrosine kinase inhibitors: real-world data from the Dutch CML registry
Sergio Rodríguez
Efficacy and safety of itovazumab in patients with steroid-refractory acute graft-versus-host disease: primary analysis of the randomized phase 2 ALTITUDE-4 study
Irina Petrov
High molecular risk mutations predicts outcome in myelofibrosis with anemia
Claire Roberts
Ibrexitamab plus inotuzumab ozogamicin in children with high-risk B-cell ALL: phase 2 results of the TRIDENT-2 trial
Sara Navarro
Prognostic value of TP53 mutations in newly diagnosed AML patients ineligible for intensive chemotherapy: results from ECLIPSE-6
Maximilian Bauer
Targeting T-cell fitness before CAR T in lymphoma: preclinical evidence
Mark Green
Multi-omic characterization of alloreactive T-cell expansion in patients with steroid-refractory acute graft-versus-host disease
Matteo Bianco
Prognostic value of inflammatory memory in aged mice: results from VIKING-8
Niklas Lindqvist
Prognostic value of GPRC5D expression in AL amyloidosis: results from AURORA-6
James Mitchell
Efficacy and safety of itovazumab in haploidentical transplant recipients: primary analysis of the phase 1 VIKING-8 study
Marie Huber
Abelorimab plus thrombopoietin receptor agonists in patients with antiphospholipid syndrome: phase 1b/2 results of the AURORA-4 trial
André Gomes
Abl1 kinase domain mutations predicts outcome in newly diagnosed chronic-phase CML
Stefanie Koch
Real-world effectiveness of abelorimab in people with severe hemophilia A: a multicenter international cohort
Cristina Romero
Multi-omic characterization of quiescent CML stem cells in newly diagnosed chronic-phase CML
Alejandro Hernández
Multi-omic characterization of bone marrow stromal support in high-risk smoldering myeloma
Serena Mancini
Marsatimab versus low-molecular-weight heparin in hemophilia B (HELIOS-2): a phase 1b/2 trial
Selin Yılmaz
Efficacy and safety of a digital symptom-monitoring program in long-term survivors of childhood leukemia: primary analysis of the randomized phase 3 NORDLYS-7 study
Richard Lewis
Real-world effectiveness of tovaclax in older patients with CLL and comorbidities: a multicenter international cohort
Andrea Neumann
Treatment patterns and survival in patients undergoing cardiac surgery: real-world data from the Dutch transfusion registry
Anil Rao
Health-related quality of life in patients with invasive fungal infections: a prospective european study
Burak Öztürk
Long-term outcomes of JAK inhibitor-naive myelofibrosis treated with hydroxyurea: a British registry study of 586 patients
Klaus Becker
Long-term outcomes of children with sickle cell disease in sub-Saharan Africa treated with hydroxyurea: a multinational registry study of 112 patients
Esther de Boer
Multi-omic characterization of immune reconstitution after bispecific antibodies in triple-class exposed myeloma
Fredrik Nyström
Efficacy and safety of orvematinib in chronic-phase CML in deep molecular response: primary analysis of the randomized phase 3 SAGA-5 study
Rasmus Hansen
Efficacy and safety of a digital symptom-monitoring program in long-term survivors of childhood leukemia: primary analysis of the randomized phase 2 CASCADE-9 study
Jürgen Keller
Health-related quality of life in patients with steroid-refractory acute graft-versus-host disease: a prospective international study
Martin Kaiser
Efficacy and safety of ravelinib in newly diagnosed chronic-phase CML: primary analysis of the phase 1b/2 VALOR-4 study
Ruben Dijkstra
Targeting lineage switch after CD19-directed therapy in acute lymphoblastic leukemia (ALL): preclinical evidence
Sebastian Jung
Single-cell profiling reveals tissue factor pathway regulation in bleeding and thrombotic disorders
Elisa Ricci
Multi-omic characterization of inflammatory aging of the stem cell niche in aged mice
Peng Zhang
A digital symptom-monitoring program versus standard supportive care in long-term survivors of childhood leukemia (NORDLYS-8): a randomized phase 3 trial
Elena Galli
Prognostic value of inflammatory memory in human cord blood: results from VALOR-7
Federica Vitale
Treatment patterns and survival in myelofibrosis after ruxolitinib failure: real-world data from the multinational MPN registry
Stephanie Brown
Quelcitamab plus azacitidine in AML in first complete remission: randomized phase 3 results of the SAGA-7 trial
Nathalie Fournier
Multi-omic characterization of lineage priming in early progenitors in human cord blood
Ruben Kok
Prognostic value of alloimmunization in patients undergoing cardiac surgery: results from CASCADE-9
Marta Gentile
Prognostic value of hepcidin levels in patients with iron deficiency anemia: results from ATLAS-5
Ha-eun Park
Prognostic value of factor VIII activity in adults with immune thrombocytopenia: results from VIKING-3
Chiara Bianco
Targeting epigenetic memory after infection in normal and malignant hematopoiesis: preclinical evidence
Alessandro Martinelli
Multi-omic characterization of iron overload and oxidative stress in adults with sickle cell disease
Frank Werner
Single-cell profiling reveals epigenetic memory after infection in normal and malignant hematopoiesis
Na Hu
A federated learning platform compared with standard diagnostic workup on multicenter flow cytometry datasets: a prospective multicenter evaluation
Sara De Luca
Validation of a federated learning platform for automated classification of bone marrow cells across 44 centers
Markus Schwarz
Clonal hematopoiesis predicts outcome in relapsed or refractory FLT3-mutated AML
Hye-jin Jung
Real-world effectiveness of whole blood in patients with massive hemorrhage: a multicenter spanish cohort
Benjamin Wood
Targeting lineage priming in early progenitors in normal and malignant hematopoiesis: preclinical evidence
Paola Conti
Targeting red cell storage lesion in transfusion practice: preclinical evidence
Luis Pérez
Long-term outcomes of hemophilia B treated with emicizumab prophylaxis: a British registry study of 188 patients
Francesco Gentile
Real-world effectiveness of telvostat in lower-risk MDS with transfusion-dependent anemia: a multicenter international cohort
Alexander Kaiser
Real-world effectiveness of mitazovat in non-transfusion-dependent beta-thalassemia: a multicenter italian cohort
Javier García
Pathogen-reduced platelets versus restrictive transfusion thresholds in preterm neonates (HELIOS-9): a phase 2 trial
Johanna Svensson
Long-term outcomes of blood donors treated with patient blood management: a international registry study of 188 patients
Elizabeth Wright
Real-world effectiveness of efactocog beta in cancer-associated venous thromboembolism: a multicenter french cohort
Alba Romero
Corvalimab versus blinatumomab in adults with Philadelphia chromosome-positive ALL (ARCTIC-1): a randomized phase 3 trial
Lin Ma
Prognostic value of undetectable MRD in treatment-naive CLL: results from PRISM-4
Jürgen Neumann
Long-term outcomes of therapy-related MDS treated with erythropoiesis-stimulating agents: a Spanish registry study of 2105 patients
Sophie Hall
Flt3-itd allelic ratio predicts outcome in NPM1-mutated AML
George Murray
Targeting transfusion-related immunomodulation in transfusion practice: preclinical evidence
Maarten van der Meer
Real-world effectiveness of mitazovat in patients with iron deficiency anemia: a multicenter international cohort
Sarah Fischer
Real-world effectiveness of tamirodene in higher-risk MDS: a multicenter french cohort
Tim Dijkstra
Tamirodene plus luspatercept in therapy-related MDS: phase 1b/2 results of the SAGA-1 trial
Roberto Caruso
Long-term outcomes of people with severe hemophilia A treated with direct oral anticoagulants: a international registry study of 812 patients
Ayumi Watanabe
Pelarisib versus ruxolitinib in myelofibrosis after ruxolitinib failure (ECLIPSE-5): a phase 2 trial
Frederik Jensen
Targeting epigenetic memory after infection in normal and malignant hematopoiesis: preclinical evidence
Anna Pettersson
Ponavatinib plus pediatric-inspired chemotherapy in adults with Philadelphia chromosome-positive ALL: randomized phase 2 results of the ALTITUDE-4 trial
Paola Costa
Efficacy and safety of ascavinib in CML after two or more tyrosine kinase inhibitors: primary analysis of the phase 2 ARCTIC-5 study
Fernanda Santos
Prognostic value of cytokine release syndrome grade in patients with sickle cell disease treated with gene editing: results from ARCTIC-5
Ting Zhao
Long-term outcomes of high-risk smoldering myeloma treated with daratumumab, bortezomib, lenalidomide and dexamethasone: a multinational registry study of 412 patients
Ananya Joshi
Vedotalimab versus tacrolimus and methotrexate in patients with steroid-refractory acute graft-versus-host disease (POLARIS-8): a randomized phase 2 trial
Panagiotis Dimitriou
Real-world effectiveness of ponavatinib in children with high-risk B-cell ALL: a multicenter dutch cohort
Shota Nakamura
Multi-omic characterization of inflammasome activation in therapy-related MDS
Ivana Horvat
Concivumab versus low-molecular-weight heparin in adults with immune thrombocytopenia (NORDLYS-7): a phase 1 trial
Evangelos Stavrou
Long-term outcomes of patients receiving CD19-directed CAR T-cell therapy treated with lymphodepletion with fludarabine and cyclophosphamide: a German registry study of 231 patients
Oliver White
Prognostic value of BCMA soluble levels in triple-class exposed myeloma: results from CORONA-6
Alexander Ward
Mezoridomide plus daratumumab, bortezomib, lenalidomide and dexamethasone in triple-class exposed myeloma: phase 1b/2 results of the SAGA-6 trial
Gil Golan
Validation of a federated learning platform for the diagnosis of myeloid neoplasms across 56 centers
Sara Lundberg
Lovotigene autotemcel plus busulfan myeloablation in patients receiving CD19-directed CAR T-cell therapy: phase 1b/2 results of the HELIOS-1 trial
Andrei Smirnov
Ravelinib versus dasatinib in chronic-phase CML in deep molecular response (BEACON-1): a randomized phase 3 trial
Réka Nagy
Linzotamab versus autologous stem cell transplantation in relapsed/refractory multiple myeloma after three prior lines (ATLAS-7): a phase 2 trial
Sébastien Richard
Single-cell profiling reveals immune effector cell-associated neurotoxicity in gene and cell therapy
Elisa Ferrara
Letermovir versus standard supportive care in long-term survivors of childhood leukemia (VALOR-1): a phase 1b/2 trial
Anders Christensen
Efficacy and safety of marsatimab in people with severe hemophilia A: primary analysis of the phase 1b/2 TRIDENT-3 study
Sergio Suárez
Real-world effectiveness of ponavatinib in adolescents and young adults with ALL: a multicenter dutch cohort
Joost Bakker
Real-world effectiveness of concivumab in adults with immune thrombocytopenia: a multicenter italian cohort
Emma Smits
Osiverol versus hydroxyurea in non-transfusion-dependent beta-thalassemia (SAGA-7): a phase 3 trial
Konstantinos Vasileiou
Efficacy and safety of telvostat in lower-risk MDS with transfusion-dependent anemia: primary analysis of the phase 2 VALOR-5 study
Julien Vincent
Prognostic value of PET-negative complete metabolic response in relapsed or refractory large B-cell lymphoma: results from HORIZON-3
Antonio Vázquez
Single-cell profiling reveals quiescent CML stem cells in chronic myeloid leukemia (CML)
Benjamin Wright
Navolatib plus ruxolitinib in JAK inhibitor-naive myelofibrosis: phase 2 results of the HELIOS-5 trial
Nicolas Laurent
Undetectable mrd predicts outcome in CLL with del(17p) or TP53 mutation
Ingrid Bakker
Efficacy and safety of ponavatinib in adults with Philadelphia chromosome-positive ALL: primary analysis of the phase 1b/2 PRISM-2 study
Georgios Papageorgiou
Health-related quality of life in adults with immune thrombocytopenia: a prospective spanish study
David Miller
Long-term outcomes of patients receiving CAR T-cell therapy treated with standard supportive care: a multinational registry study of 58 patients
Yan Yang
Health-related quality of life in chronic-phase CML in deep molecular response: a prospective french study
Matteo Bianchi
Multi-omic characterization of inflammasome activation in higher-risk MDS
Qing Gao
Efficacy and safety of rilvabrutinib in patients with antiphospholipid syndrome: primary analysis of the phase 2 VIKING-1 study
Gizem Yıldırım
Treatment patterns and survival in non-transfusion-dependent beta-thalassemia: real-world data from the German SCD registry
Magdalena Kozłowski
Single-cell profiling reveals red cell storage lesion in transfusion practice
Clément Thomas
Prognostic value of BCR::ABL1 transcript levels in chronic-phase CML in deep molecular response: results from HORIZON-6
Yael Barak
Efficacy and safety of epretamab in peripheral T-cell lymphoma: primary analysis of the phase 2 MERIDIAN-4 study
Per Persson
Long-term outcomes of adults with sickle cell disease treated with hydroxyurea: a international registry study of 231 patients
Elisa Serra
Ravotuzumab vedotin versus venetoclax and azacitidine in adults with newly diagnosed AML receiving intensive induction (VIKING-6): a phase 2 trial
Sem de Haan
A deep-learning cytomorphology model compared with standard diagnostic workup on multicenter flow cytometry datasets: a prospective multicenter evaluation
Wouter Hendriks
Talvetamab plus daratumumab, bortezomib, lenalidomide and dexamethasone in triple-class exposed myeloma: phase 2 results of the ZENITH-7 trial
Eva Roth
Targeting neutrophil extracellular traps in thrombosis in bleeding and thrombotic disorders: preclinical evidence
Lejla Novak
Prognostic value of TP53 multi-hit status in therapy-related MDS: results from VALOR-8
Anouk Hendriks
Prognostic value of platelet count increment in patients with massive hemorrhage: results from VIKING-2
Josip Begić
Osiverol versus hydroxyurea in patients with iron deficiency anemia (CORONA-9): a randomized phase 3 trial
Karin Nilsson
Health-related quality of life in lower-risk MDS with transfusion-dependent anemia: a prospective italian study
Niklas Andersson
Multi-omic characterization of T-cell fitness before CAR T in primary CNS lymphoma
Ayumi Mori
Real-world effectiveness of odrolimab in primary CNS lymphoma: a multicenter european cohort
Rohan Kapoor
Prognostic value of MRD negativity at 10^-6 in relapsed/refractory multiple myeloma after three prior lines: results from ZENITH-4
Niklas Hansson
Epretamab versus CAR T-cell therapy in relapsed or refractory large B-cell lymphoma (HORIZON-1): a phase 1b/2 trial
Tarek Haddad
Real-world effectiveness of mitazovat in non-transfusion-dependent beta-thalassemia: a multicenter international cohort
Bas Visser
Prognostic value of TET2 and DNMT3A clones in healthy donors: results from ATLAS-5
Alexander Müller
Undetectable mrd predicts outcome in fit patients with untreated CLL
Merve Özkan
Health-related quality of life in relapsed CLL after covalent BTK inhibitors: a prospective dutch study
Emma de Graaf
Long-term outcomes of transfusion-dependent beta-thalassemia treated with lymphodepletion with fludarabine and cyclophosphamide: a British registry study of 64 patients
Pauline Blanc
Prognostic value of IGHV mutational status in CLL with del(17p) or TP53 mutation: results from PRISM-6
Inês Carvalho
Long-term outcomes of higher-risk MDS treated with erythropoiesis-stimulating agents: a European registry study of 188 patients
Emily Taylor
Health-related quality of life in patients with antiphospholipid syndrome: a prospective spanish study
Yossi Shalom
Treatment patterns and survival in people with severe hemophilia A: real-world data from the multinational hemostasis registry
Giovanni Lombardi
Single-cell profiling reveals inflammatory aging of the stem cell niche in normal and malignant hematopoiesis
Ana Suárez
Long-term outcomes of cancer-associated venous thromboembolism treated with thrombopoietin receptor agonists: a Dutch registry study of 586 patients
Charlotte Garcia
Single-cell profiling reveals clonal evolution at relapse in acute myeloid leukemia (AML)
Murat Koç
Efficacy and safety of efactocog beta in patients with antiphospholipid syndrome: primary analysis of the phase 1b/2 AURORA-5 study
Joshua Moore
Menin-kmt2a dependency predicts outcome in older adults with secondary AML
Valentina Galli
Efficacy and safety of epretamab in primary CNS lymphoma: primary analysis of the phase 1 VIKING-9 study
Marta Lopes
Prognostic value of vaso-occlusive crisis rate in adults with sickle cell disease: results from MERIDIAN-6
Sander van den Berg
Long-term outcomes of newly diagnosed AML patients ineligible for intensive chemotherapy treated with azacitidine: a international registry study of 112 patients
Nicole Winkler
Health-related quality of life in patients undergoing cardiac surgery: a prospective european study
Ting Zhou
Treatment patterns and survival in patients with iron deficiency anemia: real-world data from the French SCD registry
Antonio Costa
Multi-omic characterization of lineage priming in early progenitors in healthy donors
Laurent André
Undetectable mrd predicts outcome in treatment-naive CLL
Cristina Jiménez
Treatment patterns and survival in patients with massive hemorrhage: real-world data from the German transfusion registry
Markus Frank
Multi-omic characterization of platelet desialylation in adults with immune thrombocytopenia
Beatrice Mariani
Targeting clonal dominance in myelodysplastic syndromes (MDS): preclinical evidence
Francesco Ricci
Efactocog beta plus low-molecular-weight heparin in adults with immune thrombocytopenia: phase 1 results of the VALOR-4 trial
Rachel Green
Multi-omic characterization of alloreactive T-cell expansion in patients with steroid-refractory acute graft-versus-host disease
William Williams
Measurable residual disease by flow cytometry predicts outcome in older adults with secondary AML
Elena Popov
Concivumab versus direct oral anticoagulants in cancer-associated venous thromboembolism (MERIDIAN-2): a phase 1 trial
Divya Shah
Multi-omic characterization of CAR T-cell exhaustion in patients receiving CD19-directed CAR T-cell therapy
Anastasia Theodorou
Ravotuzumab vedotin plus decitabine in NPM1-mutated AML: randomized phase 2 results of the ATLAS-2 trial
Daniel Williams
Multi-omic characterization of bone marrow stromal support in triple-class exposed myeloma
Anna Giordano
Prognostic value of TP53 multi-hit status in therapy-related MDS: results from NORDLYS-1
Noam Avraham
Single-cell profiling reveals CAR T-cell exhaustion in gene and cell therapy
Søren Madsen
Real-world effectiveness of odrolimab in primary CNS lymphoma: a multicenter french cohort
Henrik Andersson
Abelorimab plus thrombopoietin receptor agonists in hemophilia B: phase 2 results of the ATLAS-5 trial
Khaled Khalil
Validation of a large language model assistant for automated classification of bone marrow cells across 44 centers
Lauren Allen
Multi-omic characterization of epigenetic memory after infection in aged mice
Arjun Joshi
Multi-omic characterization of transfusion-related immunomodulation in preterm neonates
Johanna Larsson
Single-cell profiling reveals Richter transformation in chronic lymphocytic leukemia (CLL)
Mei Zhao
Efficacy and safety of etapivat in patients with iron deficiency anemia: primary analysis of the phase 3 CORONA-5 study
Andrew Lewis
Luspaterpin plus luspatercept in MDS with SF3B1 mutation: phase 2 results of the POLARIS-7 trial
Claire Harrison
Prognostic value of factor VIII activity in adults with immune thrombocytopenia: results from HELIOS-3
Johanna Nilsson
Treatment patterns and survival in NPM1-mutated AML: real-world data from the Spanish AML registry
Mathilde Dubois
Glovutamab versus bendamustine and rituximab in mantle cell lymphoma after BTK inhibitor failure (BEACON-5): a phase 2 trial
Nicolas Morel
Real-world effectiveness of navolatib in JAK inhibitor-naive myelofibrosis: a multicenter nordic cohort
Sarah Baumann
Efficacy and safety of cold-stored platelets in blood donors: primary analysis of the phase 3 ATLAS-4 study
Wei Zhu
Real-world effectiveness of telvostat in therapy-related MDS: a multicenter italian cohort
Stefan Becker
Health-related quality of life in myelofibrosis after ruxolitinib failure: a prospective french study
Silje Bakken
Early chimerism predicts outcome in adults undergoing allogeneic stem cell transplantation for AML
Jakub Novotný
A federated learning platform compared with expert morphological review on routine blood counts in primary care: a prospective multicenter evaluation
Feng Huang
Health-related quality of life in myelofibrosis with anemia: a prospective british study
Feng Ma
Prognostic value of patient-reported outcomes in patients receiving CAR T-cell therapy: results from TRIDENT-4
Laura Sanz
Real-world effectiveness of etapivat in children with sickle cell disease in sub-Saharan Africa: a multicenter nordic cohort
Élodie Roussel
A deep-learning cytomorphology model compared with expert morphological review on routine blood counts in primary care: a prospective multicenter evaluation
Ying Zhou
Whole blood plus restrictive transfusion thresholds in blood donors: randomized phase 2 results of the ZENITH-3 trial
Silvia Marini
Real-world effectiveness of tozarinib in relapsed or refractory FLT3-mutated AML: a multicenter european cohort
Sarah Wood
Real-world effectiveness of marsatimab in people with severe hemophilia A: a multicenter multinational cohort
Bo Hu
Spleen volume reduction predicts outcome in essential thrombocythemia
Sophie Murray
Vedotalimab versus post-transplant cyclophosphamide in older recipients of reduced-intensity conditioning (HELIOS-6): a phase 1b/2 trial
Lieke de Boer
Inclazumab versus iron chelation in pyruvate kinase deficiency (HORIZON-5): a phase 2 trial
Karolina Piotrowski
Real-world effectiveness of mezoridomide in AL amyloidosis: a multicenter italian cohort
Jian Wang
Real-world effectiveness of inclazumab in pyruvate kinase deficiency: a multicenter international cohort
Jennifer Green
Efficacy and safety of olorofim in patients receiving CAR T-cell therapy: primary analysis of the randomized phase 2 POLARIS-5 study
Fleur van der Linden
Prognostic value of undetectable MRD in relapsed CLL after covalent BTK inhibitors: results from ECLIPSE-6
Ruth Cohen
Validation of a deep-learning cytomorphology model for the diagnosis of myeloid neoplasms across 16 centers
Johanna Roth
Real-world effectiveness of marsatimab in adults with immune thrombocytopenia: a multicenter german cohort
Malin Lindberg
Treatment patterns and survival in long-term survivors of childhood leukemia: real-world data from the Nordic supportive care registry
Marloes van der Meer
Single-cell profiling reveals BCR signalling rewiring in chronic lymphocytic leukemia (CLL)
Antoine Richard
Efficacy and safety of navolatib in myelofibrosis with anemia: primary analysis of the randomized phase 3 NORDLYS-7 study
Lea Meier
Mitazovat versus hydroxyurea in patients with iron deficiency anemia (MERIDIAN-1): a phase 1b/2 trial
Philipp Lorenz
Long-term outcomes of adults with newly diagnosed AML receiving intensive induction treated with decitabine: a French registry study of 586 patients
Karl Sjöberg
Lirafenib versus venetoclax and azacitidine in adults with newly diagnosed AML receiving intensive induction (TRIDENT-4): a phase 1b/2 trial
Johan Bergström
Treatment patterns and survival in transfusion-dependent beta-thalassemia: real-world data from the British cell therapy registry
Lucas Silva
Infection-related mortality predicts outcome in long-term survivors of childhood leukemia
Jonas Ekström
Prognostic value of JAK2 V617F allele burden in JAK inhibitor-naive myelofibrosis: results from VALOR-2
Georgios Papadopoulos
Real-world effectiveness of ibrexitamab in T-cell ALL: a multicenter german cohort
Helena Ekström
Real-world effectiveness of corvalimab in T-cell ALL: a multicenter italian cohort
Min-seo Cho
Treatment patterns and survival in myelofibrosis after ruxolitinib failure: real-world data from the British MPN registry
Merve Çetin
Prognostic value of SF3B1 mutations in MDS with SF3B1 mutation: results from SUMMIT-3
Guillaume Nicolas
Multi-omic characterization of quiescent CML stem cells in newly diagnosed chronic-phase CML
Miguel Sousa
Flt3-itd allelic ratio predicts outcome in adults with newly diagnosed AML receiving intensive induction
Gábor Varga
Real-world effectiveness of whole blood in blood donors: a multicenter german cohort
Ashley Edwards
Sabrelimab versus erythropoiesis-stimulating agents in lower-risk MDS with transfusion-dependent anemia (HORIZON-9): a phase 1 trial
Serena Conte
Multi-omic characterization of ineffective erythropoiesis in higher-risk MDS
Martina Vitale
Real-world effectiveness of luspaterpin in MDS with SF3B1 mutation: a multicenter spanish cohort
Thomas Nicolas
Itovazumab versus post-transplant cyclophosphamide in adults undergoing allogeneic stem cell transplantation for AML (SAGA-3): a phase 1 trial
Vincent Blanc
A deep-learning cytomorphology model compared with expert morphological review on routine blood counts in primary care: a prospective multicenter evaluation
Mika Kimura
Prognostic value of HSC quiescence markers in healthy donors: results from CASCADE-9
Céline Girard
Efficacy and safety of orvematinib in chronic-phase CML in deep molecular response: primary analysis of the randomized phase 2 POLARIS-5 study
John Miller
Treatment patterns and survival in treatment-naive CLL: real-world data from the British CLL registry
Katherine Roberts
Sabrelimab versus luspatercept in higher-risk MDS (ALTITUDE-4): a phase 1b/2 trial
Ron Avraham
Efficacy and safety of abelorimab in people with severe hemophilia A: primary analysis of the phase 3 ECLIPSE-4 study
Juan Li
Somatic mutation burden predicts outcome in MDS with SF3B1 mutation
Ioannis Georgiou
Long-term outcomes of patients undergoing cardiac surgery treated with restrictive transfusion thresholds: a Dutch registry study of 87 patients
Ioanna Oikonomou
Targeting leukemic stem cell persistence in acute myeloid leukemia (AML): preclinical evidence
Florin Munteanu
Letermovir versus antifungal prophylaxis in patients with invasive fungal infections (NORDLYS-8): a phase 2 trial
Alice Hughes
Bcr::abl1 transcript levels predicts outcome in chronic-phase CML in deep molecular response
Giuseppe Bianco
Multi-omic characterization of inflammatory aging of the stem cell niche in human cord blood
Daan Visser
A federated learning platform compared with standard diagnostic workup on patients with suspected myeloid neoplasms: a prospective multicenter evaluation
Simone Gentile
Inclazumab versus iron chelation in adults with sickle cell disease (ALTITUDE-5): a phase 3 trial
Hannah Baumann
Targeting inflammatory aging of the stem cell niche in normal and malignant hematopoiesis: preclinical evidence
Marta Longo
Single-cell profiling reveals treatment-free remission biology in chronic myeloid leukemia (CML)
Marie Hartmann
A federated learning platform compared with expert morphological review on routine blood counts in primary care: a prospective multicenter evaluation
Matthias Scholz
Multi-omic characterization of treatment burden in long-term survivors of childhood leukemia
Laura González
Multi-omic characterization of platelet desialylation in hemophilia B
Laura Fabbri
Multi-omic characterization of immune evasion in the bone marrow niche in older adults with secondary AML
Nuria Iglesias
Real-world effectiveness of lovotigene autotemcel in recipients of allogeneic off-the-shelf CAR NK cells: a multicenter british cohort
Marco Vitale
Corvalimab plus pediatric-inspired chemotherapy in T-cell ALL: phase 3 results of the MERIDIAN-8 trial
Evangelos Nikolaidis
Treatment patterns and survival in older recipients of reduced-intensity conditioning: real-world data from the British allo-HSCT registry
Akiko Ito
Efficacy and safety of letermovir in older patients with hematologic cancers: primary analysis of the randomized phase 2 ARCTIC-3 study
Elena Conti
Rusperatide versus hydroxyurea in polycythemia vera (HELIOS-9): a phase 1b/2 trial
Hui Wang
Prognostic value of platelet count increment in patients with massive hemorrhage: results from ARCTIC-4
Nicole Anderson
Targeting leukemic stem cell persistence in acute myeloid leukemia (AML): preclinical evidence
Julia Lange
Zelvudocel versus inotuzumab ozogamicin in relapsed B-cell precursor ALL (PRISM-9): a phase 1 trial
Cristina Esposito
Validation of a federated learning platform for early detection of acute leukemia across 8 centers
Sophie White
Treatment patterns and survival in classic Hodgkin lymphoma: real-world data from the Nordic lymphoma registry
Mehmet Yıldırım
Efficacy and safety of letermovir in patients receiving CAR T-cell therapy: primary analysis of the phase 2 POLARIS-1 study
Gizem Kılıç
Efficacy and safety of telvostat in higher-risk MDS: primary analysis of the phase 1 BEACON-4 study
Pilar Fernández
Tovaclax versus acalabrutinib in relapsed CLL after covalent BTK inhibitors (ALTITUDE-6): a phase 2 trial
Gustavo Silva
Targeting clonal dominance in myelodysplastic syndromes (MDS): preclinical evidence
Alexandra Popescu
Real-world effectiveness of belosarib in older recipients of reduced-intensity conditioning: a multicenter nordic cohort
Despoina Oikonomou
Multi-omic characterization of clonal dominance in therapy-related MDS
Jing Zhu
Long-term outcomes of children with high-risk B-cell ALL treated with blinatumomab: a Italian registry study of 1240 patients
Lena Vogel
Targeting inflammatory aging of the stem cell niche in normal and malignant hematopoiesis: preclinical evidence
Murat Yılmaz
Treatment patterns and survival in NPM1-mutated AML: real-world data from the German AML registry
Sarah Schneider
Efficacy and safety of marsatimab in hemophilia B: primary analysis of the phase 1 BEACON-6 study
Arjen Jacobs
Marsatimab plus thrombopoietin receptor agonists in adults with immune thrombocytopenia: phase 1 results of the ARCTIC-9 trial
Radu Matei
Treatment patterns and survival in primary CNS lymphoma: real-world data from the international lymphoma registry
Laura Heikkilä
Single-cell profiling reveals alloreactive T-cell expansion in allogeneic stem cell transplantation
Pauline Dupont
Validation of a large language model assistant for the diagnosis of myeloid neoplasms across 31 centers
Giovanni Rizzo
Efficacy and safety of a digital symptom-monitoring program in patients with invasive fungal infections: primary analysis of the phase 1b/2 ZENITH-8 study
Silvia Domínguez
Prognostic value of early chimerism in adults undergoing allogeneic stem cell transplantation for AML: results from ATLAS-6
Fatma Yılmaz
Single-cell profiling reveals red cell membrane dysfunction in hemoglobinopathies
Nuno Carvalho
Efficacy and safety of lisarnetamab in previously untreated follicular lymphoma: primary analysis of the phase 3 TRIDENT-6 study
Jun Lin
Validation of a deep-learning cytomorphology model for automated classification of bone marrow cells across 29 centers
Scott Miller
Multi-omic characterization of alloreactive T-cell expansion in haploidentical transplant recipients
Georgia Dimitriou
Health-related quality of life in cancer-associated venous thromboembolism: a prospective italian study
Sara Rubio
Real-world effectiveness of tamirodene in therapy-related MDS: a multicenter multinational cohort
Karolina Kamiński
Efficacy and safety of nelbrutinib in treatment-naive CLL: primary analysis of the randomized phase 2 SAGA-5 study
Pavel Veselý
Prognostic value of inflammatory memory in human cord blood: results from HORIZON-6
Inês Gonçalves
Treatment patterns and survival in AL amyloidosis: real-world data from the Nordic myeloma registry
Adam Kaczmarek
Cold-stored platelets versus patient blood management in patients with massive hemorrhage (BEACON-4): a phase 2 trial
Francesco Bianco
Prognostic value of inflammatory memory in healthy donors: results from VALOR-5
Anja Kaiser
Targeting T-cell fitness before CAR T in lymphoma: preclinical evidence
Neta Biton
Treatment patterns and survival in lower-risk MDS with transfusion-dependent anemia: real-world data from the multinational MDS registry
Klara Holm
Multi-omic characterization of lineage priming in early progenitors in patients with clonal hematopoiesis of indeterminate potential
Olivier Dupont
Prognostic value of IGHV mutational status in older patients with CLL and comorbidities: results from ZENITH-4
Sven Ekström
Immune thrombocytopenia in adults
Ece Şimşek
Bleeding, thrombosis and platelets: emerging therapies
Daniel Brown
Bleeding, thrombosis and platelets: diagnosis and risk assessment
Krisztina Varga
Clonal hematopoiesis: clinical relevance
Tiago Oliveira
Hematopoiesis and stem cell biology: first-line treatment
Hyun-woo Kim
Hematopoiesis and stem cell biology: diagnosis and risk assessment
Mihai Ionescu
Primary CNS lymphoma
Jessica Turner
Lymphoma: diagnosis and risk assessment
Jing Wang
Lymphoma: managing relapse
Andrew Thompson
Quadruplet induction for newly diagnosed myeloma
Nicole Parker
Myeloma and plasma cell disorders: emerging therapies
Ulrike Meier
Myeloma and plasma cell disorders: emerging therapies
John Lewis
New oral therapies for thalassemia
Julien Lefebvre
Red cell disorders and hemoglobinopathies: long-term follow-up
Katherine Johnson
Red cell disorders and hemoglobinopathies: long-term follow-up
Sébastien Garnier
Treatment-free remission in CML: who, when and how
Óscar Hernández
Chronic myeloid leukemia: managing relapse
Federico Barbieri
Chronic myeloid leukemia: first-line treatment
Luca Vitale
Ph-positive ALL without chemotherapy
Hélène Vincent
Acute lymphoblastic leukemia: controversies and case discussion
Solveig Solberg
Acute lymphoblastic leukemia: managing relapse
Brian Edwards
Thrombosis prevention in MPN
Clara Vázquez
Myeloproliferative neoplasms: controversies and case discussion
Ana Costa
Myeloproliferative neoplasms: managing relapse
Claire Garcia
Gene therapy for hemoglobinopathies: access and long-term follow-up
Elena Matei
Gene and cellular therapy: emerging therapies
Ondřej Novotný
Gene and cellular therapy: managing relapse
Martin Vogel
Treating AML in older adults
Sung-min Choi
Acute myeloid leukemia: managing relapse
Elena Rossi
Acute myeloid leukemia: diagnosis and risk assessment
Marie Winkler
Survivorship care after hematologic cancer
László Horváth
Supportive care and quality of life: diagnosis and risk assessment
Klaus Fuchs
Supportive care and quality of life: first-line treatment
Divya Nair
Fixed-duration versus continuous therapy in CLL
Anna Lehmann
Chronic lymphocytic leukemia: emerging therapies
Alexander Müller
Chronic lymphocytic leukemia: long-term follow-up
Maya Biton
Steroid-refractory GVHD
Sophie Hahn
Stem cell transplantation: diagnosis and risk assessment
Petr Kučera
Stem cell transplantation: long-term follow-up
Uri Rosenberg
Transplantation in MDS: timing and conditioning
Liang Gao
Myelodysplastic syndromes: diagnosis and risk assessment
Keiko Yoshida
Myelodysplastic syndromes: managing relapse
Pedro Martins
Whole blood in trauma
Aleksandar Jovanović
Transfusion medicine: diagnosis and risk assessment
Miriam Schröder
Transfusion medicine: diagnosis and risk assessment
Daniel Friedrich
Artificial intelligence in the hematology laboratory
Martina Rinaldi
Novel technologies and AI: controversies and case discussion
Camilla Kristensen
Novel technologies and AI: controversies and case discussion
Tamar Golan
Immune thrombocytopenia in adults
Ana Gomes
Bleeding, thrombosis and platelets: controversies and case discussion
Clara Romero
Bleeding, thrombosis and platelets: controversies and case discussion
Lars Jacobs
Clonal hematopoiesis: clinical relevance
Linda Vos
Hematopoiesis and stem cell biology: first-line treatment
Rafael Moreira
Hematopoiesis and stem cell biology: first-line treatment
Mustafa Arslan
Acute myeloid leukemia: open questions for research
Sander de Graaf
Acute myeloid leukemia: consensus recommendations
Hao Gao
Acute myeloid leukemia: what is new in the clinic
Ryan Taylor
Stem cell transplantation: open questions for research
Gábor Szabó
Stem cell transplantation: European registries and collaboration
Rachel Moore
Stem cell transplantation: consensus recommendations
Alejandro García
Myeloproliferative neoplasms: European registries and collaboration
Martin Schwarz
Myeloproliferative neoplasms: open questions for research
Luca Barbieri
Myeloproliferative neoplasms: state of the art
Jakub Novák
Chronic lymphocytic leukemia: what is new in the clinic
Ana Navarro
Chronic lymphocytic leukemia: consensus recommendations
Pauline Legrand
Chronic lymphocytic leukemia: state of the art
Rajesh Kumar
Myeloma and plasma cell disorders: what is new in the clinic
Aurélie Roux
Myeloma and plasma cell disorders: consensus recommendations
Carolin Werner
Myeloma and plasma cell disorders: state of the art
Maja Ekström
Gene and cellular therapy: European registries and collaboration
Richard King
Gene and cellular therapy: consensus recommendations
Daniel Hughes
Gene and cellular therapy: state of the art
Emily Baker
Bleeding, thrombosis and platelets: European registries and collaboration
Marte Jensen
Bleeding, thrombosis and platelets: what is new in the clinic
Peng Li
Bleeding, thrombosis and platelets: open questions for research
Ruben van Leeuwen
Hematopoiesis and stem cell biology: consensus recommendations
Anjali Reddy
Hematopoiesis and stem cell biology: what is new in the clinic
Ron Peretz
Hematopoiesis and stem cell biology: state of the art
Martin Kaiser
Lymphoma: joint research priorities
Matteo Bianchi
Lymphoma: perspectives from both sides of the Atlantic
Sebastian Müller
Lymphoma: regional differences in practice
Alejandro Morales
Myeloma and plasma cell disorders: regional differences in practice
Sander de Vries
Myeloma and plasma cell disorders: joint research priorities
Daniel Ruiz
Myeloma and plasma cell disorders: perspectives from both sides of the Atlantic
Paweł Grabowski
Myeloproliferative neoplasms: regional differences in practice
Zsófia Németh
Myeloproliferative neoplasms: perspectives from both sides of the Atlantic
Sofia Georgiou
Myeloproliferative neoplasms: joint research priorities
Oliver Johnson
Acute myeloid leukemia: access to novel therapies
Alexander Campbell
Acute myeloid leukemia: regional differences in practice
Hiroshi Yoshida
Acute myeloid leukemia: joint research priorities
Karin van Dijk
Opening plenary lecture: Hematology at the frontier of cell and gene therapy
Rocío Navarro
Plenary lecture: Clonal hematopoiesis, aging and disease
Andrew Ward
Presidential symposium: Curing myeloma — a realistic goal?
Andreas Meyer
Presidential symposium: Precision medicine in acute leukemia
Takuya Tanaka
Presidential symposium: Equity of access to advanced therapies in Europe
Brian Scott
Best of EHA2026: malignant hematology
Maya Levi
Best of EHA2026: non-malignant hematology
Martin Vogel
Best of EHA2026: translational research
Luca Vitale
EHA Lifetime Achievement Award Lecture
Jørgen Dahl
Meet-the-Expert: Myeloproliferative neoplasms
Alba Molina
Meet-the-Expert: Supportive care and quality of life
Stefanie Roth
Meet-the-Expert: Gene and cellular therapy
Clara Rodríguez
Meet-the-Expert: Myeloma and plasma cell disorders
Petra Begić
Meet-the-Expert: Myelodysplastic syndromes
Rita Santos
Meet-the-Expert: Lymphoma
Francesca Greco
Meet-the-Expert: Acute myeloid leukemia
Arnaud Thomas
Meet-the-Expert: Stem cell transplantation
Jonas Schneider
Meet-the-Expert: Chronic myeloid leukemia
Akiko Kimura
Meet-the-Expert: Red cell disorders and hemoglobinopathies
Jonas Schwarz
Meet-the-Expert: Bleeding, thrombosis and platelets
Lucas Nascimento
Meet-the-Expert: Transfusion medicine
Divya Nair +2
Nordheim Pharma Satellite Symposium: Redefining depth of response in multiple myeloma
Bin Zhang +2
Corvalis Biotherapeutics Satellite Symposium: Bispecific antibodies across lines of therapy in B-cell lymphoma
Katherine Roberts +2
Hemavera Therapeutics Satellite Symposium: Iron, inflammation and anemia: new targets
Brian Edwards +2
Lumora Oncology Satellite Symposium: Targeting menin in acute leukemia
Ting Zhao +2
Astelis Bio Satellite Symposium: Gene therapy for hemoglobinopathies in practice
Maya Biton +2
Medrion Life Sciences Satellite Symposium: Managing triple-class exposed myeloma
Sven Ekström +2
Vireon Biotech Satellite Symposium: Allogeneic CAR T: ready for the clinic?
Arnaud André +2
Kaluna Pharma Satellite Symposium: Fixed-duration therapy in CLL
Marie Winkler +2
Cyrenna Biologics Satellite Symposium: Hemophilia care beyond factor replacement
Nikola Marić +2
Noventra Bio Satellite Symposium: Anemia in myelofibrosis
Óscar Hernández +2
Merivale Rare Disease Satellite Symposium: Complement inhibition in PNH
Jessica Turner +2
Equilibra Hemostasis Satellite Symposium: Immune thrombocytopenia in adults